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Abstract 
 
Myeloid-derived suppressor cells comprise phenotypically heterogeneous 
population of myeloid cells at different stages of differentiation endowed with 
potent immunosuppressive activity. Abnormal accumulation of MDSC in tumor 
models and cancer patients produce profound immune suppression, severely 
impairing T cell antitumor immunity, contributing to angiogenesis, cell invasion 
and metastasis, and constitute a major hurdle in achieving successful immune-
based therapies.  
Understanding the mechanism that drives MDSC expansion and enhances 
function in humans and dogs is crucial for the development of efficacious 
immunotherapy. 
Studies in dogs with several tumor types, including sarcoma, carcinomas, 
mast cell tumors and gliomas confirmed MDSC expansion in the peripheral blood 
of dog cancer patients. MDSC have been identified in dogs using the 
combination of three-marker phenotype CD11b+CD14-MHCII-cells for 
granulocytic and CD11b+CD14+MHCII-cells for monocytic subsets. Granulocytic 
MDSC accumulated in the peripheral blood of dogs with advanced sarcoma, 
carcinomas and mast cell tumors, co-purified with peripheral blood mononuclear 
cell (PBMC) fraction and expressed polymorphic mononuclear morphology. This 
subset of cells showed the ability to efficiently inhibit T cell proliferation and IFN-γ 
secretion of autologous T cells, as well as allogenic T cells from healthy dogs, 
and expressed ARG1, iNOS2, TGF-β and IL-10. Monocytic MDSC also 
 vii 
demonstrated potent ability to suppress T cell proliferation and preferentially 
accumulated in the peripheral blood of dogs with glioma. Elevated levels of 
arginase activity found in the serum of dogs with glioma could potentially be due 
to the presence of elevated numbers of MDSC. Evaluation of the anti-mouse Gr1 
antibody for MDSC staining and identification revealed that does not cross react 
and therefore is not suitable for canine cells. 
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Overview on cancer in dogs and the canine cancer model 
Approximately four million dogs are diagnosed with cancer each year in 
the United States, making cancer the leading cause of death in adult dogs and 
the major health care concern of pet owners in the United States, Australia, 
Japan and Europe (1).  
Naturally occurring canine malignances often share a wide variety of 
biologic and clinical features often observed with human cancers. There are 
many similarities between human and canine malignances including 
spontaneous neoplasm development, tumor biology, genetics, incidence rates, 
histological appearance, and response to conventional treatments (1-5). In both 
humans and dogs, tumor initiation and progression can be influenced by similar 
factors such as age, nutrition, sex, reproductive status, and exposure to 
environmental risk factors. Spontaneous tumors in dogs evolve over long periods 
of time, interacting dynamically with the host immune system, which recapitulates 
the mechanisms of tolerance observed in human disease (3). These similarities, 
the ability to collect serum, urine, blood, biopsy tissue samples, and the use of 
advanced imaging diagnostic tests to monitor clinical parameters, tumor 
progression and efficacy of the therapy make dogs with spontaneous tumors a 
strong model for translational cancer research (2, 6, 7).  
Although murine cancer models have proven to be extremely powerful to 
determine molecular pathways involved in cancer initiation, promotion, and 
progression, there are important limitations due to differences in size and 
physiology of this model. For instance, murine models do not reproduce some 
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essential features of cancer in humans; such as tumor grow over long periods, 
immune system function, tumor microenvironment and stroma interactions. More 
importantly, they have not been predictive of toxicity or efficacy of treatments in 
humans (2). 
Unquestionably, an advantage of the canine model of spontaneous cancer 
includes the possibility to develop an almost identical treatment scheme to those 
used in humans, including surgery, radiotherapy, chemotherapy, and 
immunotherapy that may better predict the response in humans to novel 
therapies. For this reason, in the past few years, translational studies using pet 
dogs have been developed to assess novel therapeutic approaches for a variety 
of cancers (1, 2, 4). 
Canine tumor models provide valuable tools for studying several aspects 
of human cancer such as identification of cancer-associated genes, the study of 
environmental risk factors, and better understanding of tumor biology and 
progression, pharmacokinetics/dynamics, toxicity, dosing, biomarkers/ endpoints, 
and adverse effects of new drugs (2, 3). Therefore, the use of canine cancer as 
model for the development of new cancer treatments has many advantages and 
makes the dog a very attractive model for oncology research and translational 
therapies (2, 3, 5). 
 
Cancer immune surveillance and tumor-immune cell interactions 
Understanding the relationship between the immune system and cancer 
began in the nineteenth century when the association between inflammation 
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against pathogens and its effect against tumors was established (8). Decades of 
studies using animal models led to the immunosurveillance theory, which 
postulated that the immune system is able to recognize and eliminate abnormal 
cancerous cells before they can develop into clinically apparent tumors (9-11).  
Increased risk of tumor development in immunodeficient or 
immunosuppressed animal models and human patients, instances of 
spontaneous tumor regression, and the presence of tumor-infiltrating 
lymphocytes and NK cells in association with improved prognosis for a variety of 
tumor types offer a compelling evidence that the immune system is capable of 
identifying and destroying nascent tumors (10-13).  
Anti-tumor immunity is accomplished by both innate and the highly 
specialized cellular and humoral components of the adaptive immune system 
(11, 13, 14). Cell mediated immune responses, especially cytotoxic T cells 
(CTLs), play a crucial role in killing neoplastic cells (13). Tumors are 
distinguished immunologically from normal tissue by the expression of self- and 
neo-antigens from aberrant genetic programs, so T cell immunosurveillance of 
malignant cells begin with recognition of these specific tumor-associated 
antigens (TAA). The binding of tumor-associated antigens to an antigen 
presenting cells (APC) and processing and presentation of these antigens to a 
cognate T cell receptor (TCR) are crucial points in the initiation of a T cell 
immune response.  
Following uptake of tumor antigens, dendritic cells (DC), one type of APC, 
traffic to lymph nodes where they processes and present tumor peptides through 
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major histocompatibility complex I (MHCI) to prime naïve CD8 T cells. This 
presentation results in T cell activation, clonal expansion and differentiation into 
tumor-specific cytotoxic T cells (CTL) capable of infiltrating tumors and 
destroying cancer cells through activation of the apoptotic caspase pathway by 
releasing the cytotoxic proteins perforin-granzyme. Therefore, activation and 
infiltration of functional effector T cells within the tumor mass is important for 
successful immunosurveillance (12, 14).  
Alternative mechanism of T cell killing occurs upon interaction between 
Fas, a member of the tumor necrosis factor (TNF) receptor family, expressed on 
the surface of tumor cells and the Fas ligand (FasL) on the surface of activated 
lymphocytes. Binding of Fas ligand to Fas leads to activation of caspases and 
apoptosis of tumor cells. However, several studies have demonstrated that many 
cancer cells developed resistance to FasL/Fas-mediated cell killing by 
expressing or secreting FasL and are therefore, capable of counteract and trigger 
the killing of activated effector T cells that infiltrate the tumor site (11, 12, 14, 15). 
Despite the presence of immune surveillance, tumors do develop in 
immunocompetent animals and humans. There are several mechanisms that 
contribute to failure of the immune system to control tumor growth such as tumor 
immunoediting, the induction of T cell tolerance, the ability of tumors to induce 
the expansion and recruitment of immune suppressive cells into the tumor 
microenvironment, activation of negative regulatory pathways and secretion of 
inhibitory factors (9, 12, 16). These mechanisms will be further discussed below. 
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Tumor Immunosuppression 
In the last decade, the majority of studies in the field of tumor immunology 
have focused on identifying tumor-specific antigens and novel treatment 
modalities to enhance immunologic responses against malignances (10, 17-21). 
Recently, an extensive amount of research is focused on understanding the 
mechanisms by which cancer cells counteract and escape the immune control, 
and therefore finding novel approaches to treat solid tumors (9, 12, 15, 17-19, 
22). 
Cancer immunoediting hypothesis describe that while the immune system 
can protect the host against tumor development, it may also serve to promote 
tumor growth and spread (11). According to this hypothesis, cancer development 
can be divided in three phases: elimination, equilibrium and escape (11-13). In 
the elimination phase, cells of the innate and adaptive immune systems detect 
and eliminate tumor cells. The second phase comprises the temporary state of 
dynamic equilibrium between immune system and tumor cells that have survived 
the elimination phase. In this phase, the immune response is strong enough to 
control, but not completely eradicate, the tumor that contains many unstable and 
genetically mutated cells. These interactions result in the selection of tumor cell 
variants capable to resist and evade the immune response. In the third phase, 
escape, less immunogenic and therefore, more resistant tumor cell variants 
develop into clinically apparent tumors (12, 13, 16, 23, 24). 
There are multiple immunosuppressive strategies by which tumors can 
attenuate the effectiveness of T cell-mediated responses. Tumors are capable of 
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avoiding recognition and cell death through downregulation or complete loss of 
immunogenic antigens and/or MHC class I molecules (16, 18, 25), 
downregulation or inactivation of death receptors (CD95/FAS or TRAIL) and 
expression of either transmembrane decoy receptors with truncated non-
functional domains or soluble decoy receptors missing the death domain (18, 
25). Tumors can also induce T cell anergy and apoptosis by signaling through T 
cell co-inhibitory receptors such as cytotoxic T lymphocyte antigen 4 (CTLA-4) or 
programmed cell death protein-1 (PD-1). Interaction of these receptors with 
members of the B-7 immunoglobulin superfamily, that are expressed primarily by 
DCs and are also upregulated in many tumor tissues, results in inhibition of T cell 
activation (16, 18, 26).  
Another major method by which tumors protect themselves from immune 
mediated elimination is by creating a dominant immunosuppressive 
microenvironment. The tumor microenvironment (TME) is composed of immune 
cells, tumor cells, stromal cells and extracellular matrix. The interactions between 
cancer cells and the host immune system in the tumor microenvironment initiate 
an immunosuppressive network that induces immune tolerance and promotes 
tumor growth (9).  
Tumor cells secrete multiple soluble suppressive factors that promote 
generation and recruitment of various immune suppressive cell types including 
myeloid-derived suppressor cells (MDSC), type 2 macrophages (M2), tumor-
associated tolerogenic dendritic cells (TADCs), and T regulatory cells (Treg) (9, 
16). Collectively, these tumor-recruited immune cells not only act to suppress an 
 8 
anti-tumor immune response but also serve to promote tumor-dependent 
angiogenesis, invasion and metastasis (27, 28).  
The most common suppressive immune cells are Tregs and MDSCs. Elevated 
levels of Treg are detected in the peripheral blood and tumors of cancer patients, 
and several studies reported that an increased number of Tregs is predictive of 
decreased survival time and poorer response to treatment (29-33). Tregs can be 
reliably identified in both human patients and mouse models by the expression of 
CD4 and CD25 surface makers and the intracellular transcription factor Forkhead 
box protein 3 (FoxP3) in both human patients and mouse models (34, 35). They 
exert suppression of T cell activity through secretion of the immunosuppressive 
cytokines transforming growth factor beta (TGF-β) and interleukin 10 (IL-10), or 
inhibit T cell activation via modulation of APC function (31). Recent studies 
demonstrated that similarly to mice and humans, Tregs also accumulate in the 
peripheral blood and tumors in dogs with a variety of cancers such as, mammary 
carcinoma (30), melanoma (36), osteosarcoma (33) and they can be identified 
using the same markers (30, 37, 38). 
The functional importance of MDSC suppressive effects on the adaptive 
immune responses has been recently appreciated and now MDSCs are widely 
accepted in the field of tumor immunology as a major contributor to immune 
suppression in cancer patients and tumor-bearing mice (39-41). 
 
Origin of myeloid-derived suppressor cells  
Myeloid cells are the most abundant hematopoietic cells in the body. They are 
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comprised of a group of distinct cell populations that have diverse functions such 
as immune protection against pathogens, elimination of dying cells and tissue 
remodeling (42). This lineage of cells originate in the bone marrow from the 
multipotent hematopoietic stem cells (HSCs) and further differentiate into various 
subsets of specialized myeloid cells such as DCs, monocytes, neutrophils, 
basophils and eosinophils. Bone marrow of healthy individuals continually 
generates immature myeloid cells that will normally develop into mature myeloid 
cells without causing evident immune suppression. On the contrary, cancer 
myelopoiesis is associated with defective myeloid cell differentiation, which 
results in the expansion and migration of immature myeloid cells to primary 
neoplastic lesions and metastases (39, 43-46). Thereby, MDSCs originate in the 
bone marrow from myeloid progenitor cells that do not differentiate into mature 
dendritic cells, granulocytes, or macrophages. Upon activation by tumor-derived-
factors, they acquire immunosuppressive properties, migrate and accumulate in 
the circulation and lymphoid tissues, and finally enter the tumor site (39, 47, 48)  
 
Accumulation of myeloid-derived suppressor cells in cancer 
Expansion of MDSC has been detected in practically all tumor models and 
human cancers. The evaluation of MDSCs in mice and in patients with different 
solid tumors demonstrates that MDSC levels were significantly higher in tumor-
bearing animals and cancer patients relative to healthy controls (39, 47, 49-53). 
These cells accumulate in the bone marrow, spleen, and peripheral blood, within 
primary and metastatic solid tumors, and to a lesser extent in lymph nodes of 
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tumor-bearing mice (39, 54-58). The majority of the studies in cancer patients 
evaluated MDSC in the peripheral blood (39, 52, 53, 59-62), however detection 
of this population of cells in the tumor site has also been reported (63). Elevated 
levels of circulating MDSC have been significantly correlated with clinical stage, 
metastatic burden and poor prognosis (52) and elimination of these cells 
dramatically improved immune responses in tumor-bearing mice and in cancer 
patients (52, 60, 64). 
In clinical patients and animal models, MDSC recruitment is driven by 
tumor burden and a variety of tumor-soluble factors produced by neoplastic and 
stroma cells in the tumor microenvironment (27, 39, 52, 55). The crosstalk 
between neoplastic cells and tumor-associated stromal cells releases key tumor-
derived factors that modulate the accumulation of immature cells and their further 
conversion into immunosuppressive cells. Several cytokines such as 
granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte 
colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-
CSF), vascular endothelial growth factor (VEGF), stem cell factor (SCF), 
transforming growth factor-β (TGF-β) and interleukin-3 (IL-3) are implicated in 
myelopoiesis and MDSC accumulation (43, 48, 55).  
GM-CSF is a cytokine that stimulates the bone marrow to produce and 
secrete granulocytes (neutrophils, eosinophils, and basophils) and monocytes 
into the blood stream while G-CSF controls the proliferation and differentiation of 
granulocytes only. Several types of cells produce GM-CSF and G-CSF including 
immune cells, fibroblasts, endothelial cells and numerous types of tumors. The 
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overproduction of these cytokines is associated with MDSC formation (43, 65). 
Importantly, although GM-CSF is used as an immune adjuvant with tumor cells 
vaccines, there is strong evidence that this adjuvant can be efficacious at low 
concentrations, but can actually provoke immunosuppression at higher 
concentrations by stimulating MDSC accumulation (56). 
Vascular endothelial growth factor (VEGF) is a growth factor secreted by 
many tumors, but it is also crucial in the formation and maintenance of normal 
blood vessels and blood cells. In addition to its well-characterized role in 
angiogenesis, VEGF has been shown to inhibit the activation of the transcription 
factor NF-κB in hematopoietic progenitor cells. This results in alterations in the 
development of multiple lineages of hematopoietic cells including inhibition of DC 
development and T cell formation, and most importantly leads to the 
accumulation of MDSC (65, 66). Gabrilovich et al. demonstrated that in vivo 
infusion of VEGF directly targeted pluripotent stem cells and led to a profound 
expansion of Gr1+ immature cells in the spleen and a less profound, but still 
significant, increase of this cell population in lymph nodes of tumor-bearing mice 
(66). A later study by Larrivee et al. showed that accumulation of CD11b+Gr1+ 
cells in bone marrow and peripheral blood are mediated through VEGFR2 
signaling and is dependent on VEGFR2-induced increases in GM-CSF. Through 
a series of experiments the authors concluded that VEGFR2 activation not only 
directly elicits the expansion of the CD11b+Gr1+ population in bone marrow and 
peripheral blood, but also the induction and secretion of GM-CSF by bone 
marrow stroma cells, which in turn exert paracrine effects on the myeloid 
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progenitor population. Therefore VEGFR2 signaling in combination with GM-CSF 
drives the rapid accumulation of CD11b+Gr1+ cells in bone marrow and peripheral 
blood (65). 
Stem cell factor (SCF) is a growth factor important for the survival, 
proliferation, and differentiation of hematopoietic stem cells and other 
hematopoietic progenitor cells. It binds to the c-kit receptor (CD117) to induce 
signaling and is also known as kit ligand. Pan et al. showed that SCF is 
expressed by many human and murine tumors and plays a role in the MDSC 
accumulation associated with advanced malignancy. Large tumor burden 
generates increased levels of SCF that can simultaneously enhance 
myelopoiesis and decrease myeloid cell differentiation, thereby inducing 
expansion of the MDSC population. Furthermore, blocking the SFC/c-kit 
signaling pathway in tumor cells led to significant decreases in MDSC 
accumulation and suppressive function, resulting in enhanced anti-tumor 
responses, tumor regression and reversion of tumor-specific T cell tolerance 
(61). 
MDSC accumulation is also associated with inflammatory processes and 
the inflammatory mediators produced during inflammation. Cyclooxygenase 2 
(COX-2) and its downstream production of prostaglandin E2 (PGE2) has been 
implicated to promote tumor progression by inducing MDSCs accumulation and 
suppressive activity (9, 43, 67, 68).  
 PGE2 is an important mediator of inflammation and is involved in other 
biological processes, including angiogenesis, apoptosis, and immune 
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suppression. (68). Recently it was reported that PGE2 is a key factor in MDSCs 
development, accumulation and functional stability. PGE2 mediates the induction 
of COX-2 in MDSCs, that initiates a positive feedback loop resulting in enhanced 
production of endogenous PGE2 (55, 62). This positive feedback between active 
COX-2-induced and autocrine production of endogenous PGE2 proved to be 
essential for stabilizing the suppressive functions of MDSCs (69). Rodriguez et 
al. showed that lung tumors constitutively express COX-1 and COX-2 and 
produce high levels of PGE2. More importantly, that signaling through the PGE2 
receptor E-prostanoid 4 expressed on MDSCs induced the production of 
arginase I contributing to T cell dyfunction (62). Fujita and colleagues 
demonstrated that gliomas express high levels of COX-2. They found that 
treatment with COX-2 inhibitors hindered systemic PGE2 production by glioma 
cells and had a direct inhibitory effect on glioma cell growth in mice (58). 
Moreover, COX-2 blockade by non-steroidal anti-inflammatory drugs (NSAID) 
significantly decreases the numbers of CD11b+Ly6GhiLy6Clo granulocytic MDSCs 
both in the bone marrow and the TME and led to increases in CXCL10 
expression and CD8+ T-cell infiltration in the TME (58). Recent work in the field 
of transplantation research has shown that large numbers of functional human 
MDSC can be efficiently generated from monocytic precursors by supplementing 
peripheral blood-isolated monocytes cultures with PGE2 (70). 
Pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-6 (IL-6), 
as well as S100A8/A9 proteins, have also been implicated in MDSC 
accumulation and suppressive function (55, 71, 72). IL-1β plays a critical role in 
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the induction and maintenance of an inflammatory TME by contributing to the 
expansion of MDSCs (71, 72). Modulation of MDSC accumulation and 
suppressive function by IL-1β is indirect, since they do not have IL-1 receptors 
(IL-1R), it occurs through induction of multiple pro-inflammatory molecules that 
contribute to the inflammatory milieu in the TME (71). On the other hand, IL-6, 
one of several downstream mediators induced by IL-1β, drives MDSC 
accumulation via direct binding of tumor-secreted IL-6 to its receptor IL-6R (55). 
The S100 inflammatory proteins S100A8 and S100A9 induce MDSC expansion 
by blocking the differentiation of myeloid precursors via a STAT3-dependent 
mechanism. In addition, S100A8/A9 proteins serve as chemotatic factors, 
contributing to the recruitment and migration of MDSCs (55). Moreover, since 
MDSC are capable to synthesize and secrete these pro-inflammatory mediators 
into the TME, S100A8/A9 proteins also promote MDSC accumulation via an 
autocrine feedback loop (57).  
Lastly, other important factors implicated in MDSC activation include the 
cytokines IFN-γ, IL-4, IL-10, IL-13 and TGFβ that are responsible for the 
induction of immunosuppressive pathways that commit immature cells to become 
functional MDSCs (43, 55, 57) and the chemotatic mediators CCL2, CCL12, 
CXCL5 that play a role in the recruitment of immature cells to the tumor stroma 
(43). 
 
Characteristics of MDSC – phenotype and subsets 
Myeloid-derived suppressor cells comprise a phenotypically 
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heterogeneous population of myeloid cells at different stages of differentiation 
that are endowed with potent immunosuppressive activity. MDSC regulate 
immune responses and tissue repair in healthy individuals and this population 
rapidly expands during many pathological conditions, including inflammation, 
infectious diseases, trauma, sepsis, and cancer (42, 64). Morphological, 
phenotypic, and functional heterogeneity is a hallmark of these cells. Due to their 
heterogeneity, they express a variety of lineage markers that overlap with other 
myeloid cells making their phenotypic characteristics broadly distinct. In mice, 
they are identified as cells with CD11b+ and Gr-1+ phenotypes (9, 39, 42, 55, 73) 
and consist of two major subsets: granulocytic MDSC (G-MDSC) identified by the 
phenotype CD11b+Ly6G+Ly6Clow and monocytic MDSC (M-MDSC) that have the 
phenotype CD11b+Ly6G-Ly6Chigh (39, 41, 47, 73, 74). These two major subsets 
of MDSC differ not only in their morphology and phenotype, but also have 
different gene expression profiles, transcription factors activity and mechanisms 
of immune suppression (64, 75). G-MDSC is the predominant subset type (70–80 
% of all MDSC), is moderately immunosuppressive and requires direct contact 
with T cells to promote tolerance. These cells suppress antigen-specific T cells 
primarily through arginase 1 (ARG1) and reactive oxygen species (ROS) 
mediated mechanisms. On the other hand, M-MDSC comprise 20–30 % of total 
MDSC, but are highly immunosuppressive, exert their suppressive effects in a 
non antigen-specific manner, and inhibit T cell function through a nitric oxide 
synthase (NOS)-mediated mechanism (42, 64, 76).  
Recent research suggests that these subsets are not distinct, fully 
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differentiated populations. Youn et al. demonstrated that M-MDSC have the 
ability to dedifferentiate into immunosuppressive G-MDSC through the loss of 
expression of Retinoblastoma (Rb) protein; a process that is mediated by 
epigenetic silencing of the Rb gene (75). 
In humans, the MDSC phenotype is less clearly defined, so combinations 
of various markers have been used to identify this population in the peripheral 
blood of cancer patients. They can be defined as cells that co-purify with 
peripheral blood mononuclear cells and lack expression of lineage specific cell 
markers of lymphocytes, natural killer cells and DCs, as well as markers of 
mature myeloid cells such as HLA-DR, CD40, CD80 and CD83. However they 
express the common myeloid markers CD33 and CD11b, and depending of the 
subset express the granulocyte marker CD15 or monocyte marker CD14, for 
human G-MDSC and M-MDSC, respectively (40, 52, 59, 77, 78).  
Therefore variable phenotypes have been described in different types of 
human cancer to identify this heterogeneous and complex cell population. It has 
been suggested that human granulocytic MDSC can be identified as Lin- HLA-
DR-CD33+ or CD11b+CD14-CD15+ while the monocytic subset expresses 
CD11b+CD14+ HLA-DR-/low   or CD14+ HLA-DR-/low (42, 55, 64, 77, 78).  
An extensive amount of research is underway to better identify potential 
MDSC subsets and new ways to target these cells (17, 40, 49, 59, 61, 63, 68, 74, 
75, 77, 79-90). Recently IL-4R alpha (IL4Rα) has been identified as a potential 
marker for highly immunosuppressive monocytic MDSC in mice and humans (84, 
91). The activation marker CD66b has been described in granulocytic MDSC 
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subsets (59) and the VEGF-R can also be expressed by human MDSC (59, 60). 
Therefore, the biology of MDCS is very complex and they express varied 
phenotypes and suppressive patterns, likely depending on the cytokine profile in 
the TME. The large number of candidate markers emphasizes the complexity in 
defining these cells, possible due to the dynamic plasticity of these cells and their 
ability to readily respond to tumor-derived factors (41, 43, 78).   
 
Mechanisms of MDSC immunosuppression 
Myeloid-derived suppressor cells have become the focus of intense study 
in recent years. This distinct population of cells is now widely recognized as 
critical mediators of tumor escape and progression in various solid tumors (39, 
42, 54, 92). MDSC play a crucial role in the regulation of anti-tumor immunity, as 
well as contribute to angiogenesis, cell invasion and metastasis (93). Although 
heterogeneity is a hallmark of this population, all MDSC share a common trait, 
the extraordinary ability to suppress T cell responses (27, 39, 41, 42, 55, 93, 94). 
Several underlying mechanisms of MDSC immunosuppressive activity have been 
described and their overall biological role is now widely appreciated. Up-
regulation of ARG1, inducible nitric oxide synthase (iNOS), and ROS has been 
implicated as a major factor in the immune suppressive activity of MDSC (42, 54, 
94). Therefore, their immunosuppressive mechanisms can be separated into two 
groups: L-arginine-dependent, directly affecting T cell function, and L-arginine- 
independent, inducing expansion of other suppressive cells such as Tregs (42). 
MDSCs express high levels of ARG1 and iNOS2 resulting in the rapid 
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depletion of the semi-essential amino acid, L-arginine. Decreased levels of L-
arginine lead to loss CD3 ζ-chain expression and dysfunction of other signal 
transduction components, including tyrosine kinase and Janus-kinase-3, thereby 
blocking activation-proliferation signals and inhibiting tumor-specific T cell 
responsiveness (42, 73, 93, 95). In addition to L-arginine depletion, accumulation 
of nitric oxide (NO), a metabolite of iNOS2 activity, induces apoptosis of T cells 
through accumulation of p53 by FAS or caspase-independent signaling (42). 
Moreover, MDSCs induce nitration-nitrosylation of the TCR-CD8 complex 
through hyper-production of reactive oxygen species (ROS) and peroxynitrites 
during direct cell-cell contact. This change in the TCR-CD8 complex results in 
disruption of T cell function and promotes nitration of the chemokines such as 
CCL2 in the TME impairing trafficking of tumor-specific T cells to the tumor site. 
Furthermore, MDSC prevent T cell activation and function by decreasing the 
availability of extracellular cysteine, an amino acid required for T cell activation 
and function (42).  
An indirect MDSC mechanisms by which MDSC inhibit T cell function is 
the development and expansion of T regulatory cells, mediated by secretion of 
immunosuppressive cytokines TGF-β and IL-10 (42, 61, 80, 93). Moreover, 
increases in IL-10 / TGF- β production are also associated with decreases in IL-
12 production by macrophages, which induces NK and T cell anergy (93).  
MDSC have also been demonstrated to support neoangiogenesis, tumor 
growth and metastasis (27). These cells have the ability to invade into the tumor 
and secrete pro-angiogenic factors, such as VEGF. In addition, MDSC produce 
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matrix metalloproteinases (MMPs) and chemoattractants, such as S100A8 and 
S100A9 pro-inflammatory proteins, which induce a pre-metastatic environment 
that leads to cancer invasion and metastasis (27, 55, 71, 93).  
Given the variety of mechanisms employed by MDSC, they have a 
tremendous potential to suppress immune responses and assist in tumor 
progression and therefore, constitute an important and promising target to 
improve the efficiency of new cancer treatments, such as immunotherapy. 
 
MDSC as therapeutic targets 
Over the past two decades, it has become evident that tumor-associated 
immunosuppression contributes significantly to tumor progression and resistance 
to cancer immunotherapy (16, 17, 19, 96). 
Since accumulation of MDSC in cancer patients severely impairs a T cell 
response and constitutes a major hurdle in achieving successful immunotherapy, 
several therapeutic strategies to block function, differentiation, expansion and 
accumulation of these cells have been developed (reviewed in (89)). Multiple 
methods to inhibit MDSCs are currently under investigation. They can be broadly 
categorized into methods that 1) functionally inhibit MDSC (phosphodiesterase-5 
inhibitors, COX-2 inhibitors), 2) promote differentiation of MDSC into mature, 
non-suppressive cells (all-trans-retinoic acid, vitamin D), or 3) decrease MDSC 
levels (sunitinib, gemcitabine, 5- fluorouracil).  
Therapeutic approaches to inhibit MDSC immunosuppressive function 
include ARG1 inhibitors, NO inhibitors, ROS inhibitors, and migration inhibitors. 
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Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, have been show to 
decrease expression of both ARG1 and iNOS2 and improve T cell function in 
patients with head and neck squamous cell carcinoma (HNSCC) and multiple 
myeloma (87). Based on encouraging preclinical results, several clinical trials 
using phosphodiesterase-5 (PDE-5) inhibitors have been initiated. Nitroaspirin 
has been demonstrated to effectively suppress the production of ROS in MDSC 
(89). COX-2 reduces the immunosuppressive function of MDSC by decreasing 
expression of ARG1, but is also associated with significant decreases in MDSC 
numbers (58, 62).  
All-trans-retinoic acid (ATRA), a metabolite of vitamin A, induces MDSC 
maturation and expression of differentiation markers such as HLA-DR (82, 85). 
High doses of Vitamin D3 or A can induce maturation of myeloid cells and 
upregulation of HLA-DR increasing anti-tumor immunity. Moreover, CpG 
oligodeoxynucleotides (ODN) induce maturation of MDCS by stimulating the 
production of IFNα by cytoplasmoid DC (90).  
Sunitinib is a FDA-approved multi-kinase inhibitor for the treatment of 
advanced renal cell carcinoma that has multiple targets including VEGFR and c-
kit. Human studies demonstrate that sunitinib treatment significantly decreases 
circulating MDSC and Tregs in renal cell cancer patients, which resulted in 
increased T cell function (60).  
Moreover, while some chemotherapeutic agents, such as doxorubicin and 
cyclophosphamide, have been shown to increase MDSC levels in peripheral 
blood of cancer patients (52), other conventional cytotoxic compounds such as 
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gemcitabine, cisplatin, 5-fluorouracil (5-FU) and docetaxel have been show to 
have cytotoxicity effects on MDSC (89). The use of genetic engineered 
molecules, such as IL4Rα-aptamer to specific target IL4Rα on MDSC, was 
demonstrated to efficiently induce MDSC apoptosis (97). 
Therefore, there are multiple strategies that can be employed to target 
these immunosuppressive populations and new combination therapies utilizing 
these approaches to decrease the immunosuppression of cancer patients could 
potentially enhance the effectiveness of cancer immunotherapy. 
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Summary 
Dogs with naturally occurring cancer represent an important large animal 
model for drug development and testing novel immunotherapies. However, 
poorly defined immunophenotypes of canine leukocytes have limited the study of 
tumor immunology in dogs. The accumulation of myeloid derived suppressor 
cells (MDSCs) is known to be a key mechanism of immune suppression in tumor-
bearing mice and in human patients. We sought to identify MDSCs in the blood 
of dogs with cancer. Peripheral blood mononuclear cells (PBMCs) from dogs with 
advanced or early stage cancer and from age-matched healthy controls were 
analyzed by flow cytometry and microscopy. Suppressive function was tested in 
T cell proliferation and cytokine elaboration assays. Semi-quantitative RT-PCR 
was used to identify potential mechanisms responsible for immunosuppression. 
PBMCs from dogs with advanced or metastatic cancer exhibited a significantly 
higher percentage of CD11b+CD14-MHCII-cells compared to dogs diagnosed 
with early stage non-metastatic tumors and healthy dogs. These CD11b+CD14-
MHCII- cells constitute a subpopulation of activated granulocytes that co purify 
with PBMCs, display polymorphonuclear granulocyte morphology, and 
demonstrate a potent ability to suppress proliferation and IFN-γ production in T 
cells from normal and tumor-bearing donors. Furthermore, these cells expressed 
hallmark suppressive factors of human MDSC including ARG1, iNOS2, TGF- β 
and IL-10. In summary our data demonstrate that MDSCs accumulate in the 
blood of dogs with advanced cancer and can be measured using this three-
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marker immunophenotype, thereby enabling prospective studies that can monitor 
MDSC burden. 
We have found significant increases in arginase enzymatic activity in the serum 
of dogs with gliomas compared with healthy controls. Therefore we proposed that 
the elevated levels of arginase activity in these patients, could be due to the 
increased MDSC percentages 
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Introduction 
Tumors in dogs progresses relatively faster than the same disease in 
humans, allowing questions related to treatment efficacy (progression and 
survival) to be addressed more rapidly in dogs. An important advantage of the 
dog model is the ability to test experimental therapeutics at human scale doses in 
the setting of minimal residual disease, which is difficult to do in a meaningful 
way in small rodents that have relatively rapid tumor growth kinetics. In addition, 
because the standard of care for most canine tumors is poorly established, there 
is much more flexibility in study design compared to human clinical trials. 
Collectively these features make the dog an outstanding platform for translational 
medicine.  
Pet dogs with cancer are rapidly becoming an important tool used in drug 
development. One of the best examples of this is the recent parallel development 
of SU11654, a multi-targeted tyrosine kinase inhibitor, and sunitinib malate 
(SU11248). Both drugs are potent inhibitors of PDGFR, VEGFR, KIT, and FLT3. 
Studies in dogs with various solid tumors revealed that plasma concentration of 
SU11654, the mutational status of KIT, and the inhibition of KIT phosphorylation 
were strongly predictive of clinical efficacy. Optimal dosing parameters and 
toxicity were established in dogs as well. These pioneering studies greatly 
facilitated the further development of this entire class of drugs, most notably the 
approval of sunitinib malate by the U.S. Food and Drug Administration for the 
treatment of renal cell carcinoma (RCC) and gastrointestinal stromal cell tumors, 
which often contain similar KIT mutations (98). It was later recognized that 
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sunitinib markedly depletes MDSCs and restores T cell function in human RCC 
patients (60), an observation that could not have been made in dogs at the time 
because of limited canine reagents and poorly defined markers for canine 
leukocytes. We, and others, are testing novel immune-based therapies in dogs 
with various malignancies, but immune monitoring in these studies has been 
confounded by the same problem. To put the field in perspective, a surface 
immunophenotype for canine natural killer cells has not been defined, the MHC 
alleles are poorly understood, and many of the markers used rely on cross-
reactive antibodies whereby specificity must be tested empirically. It is crucial 
that new reagents are developed and that the immunophenotypes of all major 
canine leukocytes subsets are determined. Laying this basic foundation will allow 
unique insights to be made as new small molecule drugs and immunotherapies 
are tested in dogs as a prelude to human trials. 
The accumulation of MDSCs in tumor-bearing mice and humans with 
cancer is known to be a key mechanism of tumor escape from immune 
surveillance (52, 55, 73). MDSCs comprise a phenotypically heterogeneous 
population of myeloid cells in early stages of differentiation that expand in cancer 
and many other pathological conditions, and have a potent ability to suppress T 
cell function, especially T cell proliferation and effector cytokine production (64, 
73, 95). MDSCs may be divided into monocytic and granulocytic subtypes. One 
source of controversy in this field is that MDSC heterogeneity has made 
comparisons between cancer patients and murine tumor models challenging (see 
reference (64) for excellent perspective).  
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The molecular mechanisms by which MDSCs inhibit T cell function are 
under investigation. Studies have implicated up-regulation of arginase 1 (ARG1), 
inducible nitric oxide synthase (iNOS2) and reactive oxygen species (ROS) as 
important factors for MDSC-mediated immune suppression (39, 41, 64, 95). 
ARG1 can profoundly impair T cell function at the tumor site by L-arginine 
depletion, triggering the amino acid starvation response and apoptosis in 
lymphocytes (55). Another mechanism of immune suppression is chemokine 
nitration, which blunts effector T cell infiltration into the tumor site (99). 
Furthermore, MDSC expansion is associated with downregulation of L-selectin 
on CD4+ and CD8+T cells. This reduces T cell trafficking to secondary lymphoid 
organs where tumor-reactive T cells can be primed (100).  
Due to the ability of MDSCs to down regulate the immune response 
against tumors in mice and in humans, we hypothesized that these cells would 
also play an important role in tumor-induced immune suppression in dogs with 
cancer. Hence, the objective of this study was to identify surface markers that 
characterize the existence of MDSCs in dogs. 
 
Materials and Methods 
Study Population and sample collection  
The description of all dogs in this study is summarized in Tables 1 and 2, 
with further detail provided in Tables S1 and S2. Table S3 is a summary of 
samples assayed in each figure. Clinical data were obtained from medical 
records. Control dogs were determined to be healthy based on physical 
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examination, owner observations, and complete blood count exams. For dogs 
with cancer, the diagnosis and tumor staging were based on complete physical 
examinations, histopathology of tumor biopsy specimens, blood work and 
specialized imaging tests, such as CT scans, ultrasound or radiographs, to 
assess tumor location and size, as well as the presence of metastatic disease. 
Dogs with large, necrotic or multiple masses, lytic or severe bone destruction 
(with osteosarcoma) or presence of metastasis, were placed into the advanced 
stage/metastatic group. Animals presenting with small masses or no metastatic 
nodules were placed into the early stage non-metastatic group. Tables S1 and 
S2 also list specifics about any treatment that dogs with cancer had received 
prior to or at the time of blood collection for this study. Blood samples from both 
cancer and healthy control dogs were obtained specifically for this study. 
Samples were collected in heparinized tubes by the Oncology and Community 
Practice Services of the Veterinary Medical Center at the University of Minnesota 
according to Institutional Animal Care and Use Committee guidelines. The 
samples were drawn after the owners signed the client consent form. The 
Institutional Animal Care and Use Committee (IACUC) reviewed and approved 
the study entitled as ‘‘Flow Cytometric Immunophenotyping of Peripheral Blood 
Cells in Dogs’’ via designated member review under the code number 
0912A75493. Unless explicitly stated otherwise, the cells being analyzed for this 
manuscript co-purified with peripheral blood mononuclear cells (PBMCs) of dogs 
with cancer or age matched healthy controls that were isolated using Ficoll 
(Sigma) gradient centrifugation as follows. Heparinized peripheral blood was 
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diluted 1:3 with sterile PBS (Invitrogen) and layered over Ficoll-Histopaque 
(Sigma). Samples were centrifuged at 400-xg for 30 min. The PBMCs collected 
at the interface were transferred to a fresh tube, washed twice with PBS, and 
resuspended with freezing solution consisting of 90% fetal bovine serum 
(Invitrogen) 10% Dimethyl sulfoxide (DMSO) (Sigma) and then frozen at -80°C. 
Lastly, PBMCs were thawed for 2 minutes in a 37°C water bath before staining 
and analysis. For analysis of fresh samples, PBMCs were isolated as above, 
resuspended in FACS buffer, stained with antibodies, and immediately analyzed 
by flow cytometry or FACS as indicated. 
 
Flow Cytometric Analysis 
PBMC samples were isolated from fresh blood or thawed and 
resuspended in FACS buffer. Nonspecific antibody binding was blocked by 
pretreatment of cells with 10 mg/mL canine gamma globulin (Jackson 
Immunoresearch) for 20 min at room temperature. Cells were first labeled using 
indirect staining with 0.1 mg of unconjugated mouse anti-dog CD11b antibody 
(clone CA16.3E10, AbD Serotec) or IgG1 isotype control (AbD Serotec) and 0.5 
mg of PE-conjugated goat F(ab’)2 anti-mouse IgG (Abcam) secondary antibody 
at 4°C for 30 min in a dark room. Following indirect staining, cells were washed 
twice and stained with 0.3 mg of FITC-conjugated rat anti-dog MHCII (clone 
YKIX334.2, AbD Serotec) and 0.15 mg of the cross-reactive, Alexa fluor 647- 
conjugated mouse anti-human CD14 antibody (clone TU¨ K4, AbD Serotec) or 
isotypes controls at 4°C for 30 min in a dark room according to manufacturer’s 
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protocol. Antibody-labeled cells were washed twice and re-suspended in FACS 
buffer. Cells were incubated for 10 minutes at room temperature in the dark with 
7-amino-actinomycin D (7AAD, final concentration of 1 mg/mL; Calbiochem) and 
then analyzed on a Becton Dickinson Canto three-laser flow cytometer. Data 
were further analyzed with FlowJo software (Tree Star). Analysis gates were set 
based on the 7AAD negative population. The percentage of MDSCs was 
calculated based on the percentage of CD11b+CD14-MHCII-cells within the 
overall live PBMC population. In one experiment (Figure S1), anti-mouse PE 
conjugated CD11b (clone M1/70 eBioscience) and anti-mouse APC-conjugated 
Gr-1 (clone RB6-8C5 eBioscience) antibodies were also used to verify cross 
reactivity with dog cells. 
 
Isolation of MDSCs, PMNs and T cells  
For functional assays, RT-PCR and cell morphology analysis, fresh blood 
samples from a tumor-bearing dog were used for isolation of CD11b+CD14-
MHCII- or CD11b+CD14+MHCII- cells, as indicated, using a BD FACS Aria cell 
sorter. For T cell isolation, PBMCs were isolated as previously described from 
fresh blood samples of healthy dogs and stained with 0.3 mg of FITC-conjugated 
mouse anti-dog CD3 (clone CA17.2A12, AbD Serotec), 0.15 mg of Pacific blue-
conjugated mouse anti-dog CD4 (clone YKIX302.9, AbD Serotec) and 0.15 mg of 
Alexa700-conjugated mouse anti-dog CD8 (clone YCATE55.9, AbD Serotec) 
antibodies. Polymorphonuclear leukocytes (PMN) were purified from the cell 
pellet of a Ficoll gradient from healthy dog blood samples, after removal of the 
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PBMCs (at the top of gradient) and erythrocytes by RBC lysis buffer 
(eBioscience). 
 
Ex Vivo Proliferation  
Analysis of MDSC inhibitory activity on T cell proliferation was measured 
by 3H-thymidine incorporation into DNA. Briefly, PBMCs from the indicated dogs 
were seeded into U-bottom 96- well plates (5x104cells/well) in medium consisting 
of RPMI 1640 containing L-arginine (150 mM) (Invitrogen) supplemented with 
penicillin/streptomycin (Invitrogen) and 10% heat-inactivated fetal bovine serum 
(Invitrogen) at 37°C, in a 5% CO2 incubator. CD11b+CD14-MHCII- or 
CD11b+CD14+MHCII- cells from a dog with cancer were sorted and added to 
cancer (autologous) or healthy responder PBMCs as indicated. Concanavalin A 
(5 mg/ml) (Sigma) and recombinant human IL-2 (10 IU/ml) (R&D systems) were 
used to stimulate T cell proliferation. Non-stimulated PBMCs were used as 
negative control. PBMCs or PMNs were co-cultured with healthy PBMCs to 
control for the effect of simply adding additional cells to the suppression assay as 
indicated. Plates were cultured for 72 h, and then pulsed with 1 µCi of 3H-
thymidine (Amersham Pharmacia Biotech) for 18 hrs at 37°C. Cells were 
harvested onto glass fiber filters (Perkin Elmer), washed, dried, and counted. 
Proliferative responses were measured by 3H-thymidine incorporation into the 
DNA using a Matrix 96 Direct Beta Counter (Packard). All experiments were 
performed in triplicate.  
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IFN-γ  Analyses 
 FACS-isolated CD11b+CD14-MHCII- cells from a cancer dog were co-
cultured with PBMCs isolated from a healthy dog using the same method as the 
proliferation assay. After 72 hrs of incubation the cell culture supernatants were 
collected and measured using a Quantikine canine IFN-γ ELISA kit according to 
the manufacture’s instructions (R&D systems). Samples were assayed 
colorimetrically, in triplicate, using a Microplate Reader Synergy2 (Biotek) and 
analyzed with Microplate Data Collection and Analysis Software Gen5 (Biotek). 
 
Cytospin 
 FACS-isolated CD11b+CD14-MHCII- cells were stained using a modified 
Giemsa stain (Diff-quick, Astral Diagnostics Inc) for cell morphology evaluation 
and observed using a DME microscope (Leica) at 63X power magnification. 
Pictures were acquired with an EC3 camera (Leica). 
 
RNA extraction and RT-PCR 
RNA was extracted from FACS-isolated CD11b+CD14-MHCII- cells or 
healthy dog PMNs, using an RNAeasy plus Mini kit (QIAGEN) according to the 
manufacturer’s protocol. RNA concentrations were evaluated using a ND (100) 
spectrophotometer (Nanodrop). To detect expression of ARG1 and iNOS2 
enzymes, gene-specific primers were designed based on the canine ARG1 and 
iNOS2 sequence; primer sequences for housekeeping gene were designed from 
canine b-actin gene using Primer3Plus (http://www.bioinformatics.nl/cgi-
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bin/primer3plus/ primer3plus.cgi). For detection of cytokines IL-10 and TGF- β 
primer sequences of IL-10 and TGF- β were obtained from published sources 
(37). The BLAST algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to 
ensure primer specificity to the target gene. First strand cDNA synthesis was 
done using a QuantiTect Reverse Transcription kit (QIAGEN). The two-step PCR 
reaction was carried out in a 12.5-ml volume containing 26SYBR green master 
mix (Quanta Biosciences), 0.675U GoTaq Polymerase, 2 nM MgCl2 (Promega), 
0.2 mM dNTPs (Stratagene), 0.2 mM of each primer pair and 50 ng of cDNA 
template. Reaction conditions consisted of initial denaturation at 94uC for 2min, 
then cycles of denaturation at 94uC for 30 s, annealing at 60uC for 45 s, 
elongation at 72uC for 45 s and final elongation at 72uC for 5 min in a DNA 
Engine Thermal Cycler (Bio-rad). The optimum annealing temperature for each 
primer pair was established prior to the study (see primer sequences in Table 
S4). PCR products were run on 2% agarose gels containing 0.5 ml ethidium 
bromide and imaged under 590 nm ultraviolet light on an Eagle Eye II image 
station (Stratagene). Negative control reactions were performed using RNA that 
was not subjected to reverse transcription PCR. 
 
Statistical Analysis 
The differences between two groups were analyzed using unpaired, two-
tailed Student’s t test. All tests were performed with Prism 4 software (Graph Pad 
Software, Inc). P values, 0.05 were considered to be statistically significant. 
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Results 
Dogs with advanced cancer have elevated levels of granulocytic 
CD11b+CD14-MHCII- cells that co-purify with PBMCs 
Peripheral blood samples from 45 dogs diagnosed with cancer and 18 
healthy control dogs were collected (Tables 1 and 2). All dogs with cancer 
underwent clinical staging of their disease by performing complete physical 
examinations, blood work, imaging to assess tumor location and size and 
metastases, and histopathological diagnosis made from diagnostic aspirate or 
biopsy of the tumor. Among the 45 dogs diagnosed with cancer, 30 dogs were 
classified as having advanced or metastatic disease and 15 dogs were classified 
as early stage/non-metastatic or low grade disease based on clinical staging. 
Each group was further subdivided according to histological diagnosis into 
sarcomas, carcinomas or mast cell tumors (detailed in Tables S1 and S2). 
The percentages of putative MDSCs in dogs with cancer and healthy dogs 
were evaluated by flow cytometry. PBMCs from dogs with advanced or 
metastatic cancer showed a marked increase in the CD11b+CD14-MHCII- fraction 
of cells, which accounted for the majority of the cells in the live cell gate, 
compared to dogs diagnosed with early stage non-metastatic tumors or healthy 
dog controls (Fig. 1A). This subset of cells exhibited a polymorphonuclear 
granulocytic morphology at heterogeneous stages of development (Fig. 1B), 
which resembles a granulocytic subset of MDSCs identified in mice (101) and 
humans (102). 
Dogs with advanced or metastatic cancer had a significantly greater 
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fraction of putative MDSCs (36.04±2.542, mean±SEM) compared to dogs with 
early stage non-metastatic tumors (9.40±0.953, mean±SEM) and healthy control 
dogs (10.24±1.412, mean±SEM) (Fig. 2A). Moreover, this elevation in the 
CD11b+CD14-MHCII- fraction did not appear to be restricted to a specific tumor 
type. The differences were statistically significant in dogs with sarcomas, 
carcinomas, and mast cell tumors compared with healthy controls (Fig. 2B). 
Conversely, the percentage of CD11b+MHCII- cells that did express CD14 was 
not significantly different among any group. Therefore, the frequency of CD11b+ 
CD14-MHCII- cells that co-purify PBMCs correlates with tumor burden. This 
finding is in agreement with previously published data regarding MDSC levels 
and tumor burden in mice and humans (53, 103). 
 
CD11b+CD14-MHCII- cells are functionally defined as MDSCs 
To test whether the CD11b+CD14-MHCII- subset was able to inhibit T cell 
function, we conducted a series of co-culture experiments. Purified 
CD11b+CD14-MHCII- cells from three different subtypes of cancer were co-
cultured with autologous or healthy responder PBMCs. In all cases, 
CD11b+CD14-MHCII- cells exhibited a potent ability to suppress proliferative 
responses in a dose-dependent manner. Representative examples of 
proliferative suppression are shown using samples from a dog with tonsillar 
squamous cell carcinoma (Fig. 3A) and prostatic adenocarcinoma (Fig. 3B).  
In order to determine if suppression was an artifact of using responders 
from tumor-bearing dogs, we assayed for proliferative suppression using normal 
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responders. The addition of CD11b+CD14-MHCII- cells, but not normal PMNs, 
impaired the proliferation of PBMCs from healthy dogs (Fig. 3C). Moreover, the 
amount of IFN-γ secretion was assessed in the conditioned medium from these 
co-cultures, revealing that CD11b+CD14-MHCII- cells, but not normal PMNs, 
suppressed the secretion of IFN-γ (Fig. 3D). 
 
CD11b+CD14-MHCII- cells suppress both CD4+ and CD8+ T cells 
To further interrogate the direct effect on T lymphocytes, purified 
CD11b+CD14-MHCII- cells from a dog with osteosarcoma were co-cultured with 
purified CD4+ and CD8+T cells from a healthy dog for 72 h. Non-stimulated cells 
and CD4+ and CD8+cells co-incubated with healthy PBMCs were used as 
controls. As expected, CD11b+CD14-MHCII- cells inhibited the proliferation of 
CD8+ (Fig. 4A) and CD4+T cells (Fig. 4B) while PBMCs from a normal dog did 
not. Taken together, these data demonstrate that CD11b+CD14-MHCII- cells are 
indeed functionally defined as canine MDSCs. 
 
CD11b+CD14-MHCII- cells express hallmark MDSC-derived 
immunosuppressive factors 
It has been shown that MDSCs can inhibit T cell function by the production 
of soluble factors such as arginase-1, reactive oxygen species, nitric oxide, and 
TGF- β (8–10). In order to assess whether CD11b+CD14-MHCII- cells from dogs 
with cancer could possibly utilize these mechanisms to mediate T cell 
suppression, we evaluated the expression of ARG1 and iNOS2, as well as the 
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immunosuppressive cytokines TGF- β and IL-10, within this cell population and 
from PMNs isolated from peripheral blood of healthy dogs. PCR analysis of RNA 
extracted from FACS isolated CD11b+CD14-MHCII-cells confirmed the 
expression of ARG-1, iNOS2 enzymes and immunosuppressive cytokines TGF- 
β and IL-10 mRNA (Fig. 5A). In contrast, normal dog PMNs did not express 
ARG1, although iNOS, TGF- β and IL-10 mRNA were detectable (Fig. 5B). 
Because mRNA for ARG-1, iNOS2, TGF-β and IL-10 were all found, we conclude 
that these factors could play a role in the inhibition of T cell proliferation and 
effector function. However, since PMNs isolated from healthy dogs did not 
express detectable ARG-1 mRNA or impair T cell function, suggesting that ARG-
1 may be a tumor-induced mechanism that MDSCs could employ for T cell 
suppression. This finding was not unexpected and has been previously 
documented in human MDSC studies (59). 
 
Discussion 
The field of comparative oncology shows great promise to advance the 
development of novel therapeutics for pet dogs and human patients alike. 
However, the paucity of reagents and poorly defined immunophenotype of canine 
leukocytes has restrained our ability to understand tumor immunology in dogs 
with naturally occurring cancer.  
Our data demonstrates the existence of MDSCs in the peripheral blood of 
dogs, which are elevated in all types of advanced or metastatic cancer analyzed 
compared to early stage non-metastatic cancer and healthy controls. With this 
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basic foundation of knowledge in place, it will now be possible to prospectively 
monitor MDSC burden in dogs treated with experimental drugs and 
immunotherapy.  
The CD11b+CD14-MHCII- cell population that we defined as MDSC co-
purified with PBMCs, had polymorphonuclear granulocytic morphology, 
suppressed T cell proliferation and effector function, expressed hallmark 
suppressive factors of human MDSC, and positively correlated with tumor 
burden. Proliferation assays revealed relatively weak proliferation in PBMCs from 
tumor-bearing dogs (Fig. 3A,B) compared to normal responders (Fig. 3C) in the 
absence of exogenous MDSC. This likely reflects elevated levels of endogenous 
(not experimentally added) MDSCs and regulatory T cells in the PBMCs from 
dogs with cancer. Furthermore, it is crucial to note that a second subset of MDSC 
that is more monocytic in nature is widely appreciated in murine and human 
tumor immunology. We found no evidence for selective expansion of a 
CD14+monocyte-like cell in the blood of dogs with cancer. However, 
CD11b+MHCII- cells that were purified from dogs with advanced cancer that were 
also CD14+ potently inhibited T cell proliferation (Figure S2), revealing that 
although monocytic MDSC are not a dominant population in dogs with cancer, 
they are indeed present. This finding of preferential expansion of granulocytic 
MDSC is not surprising and is in agreement with similar studies carried out in 
murine tumor models (101).  
Overall, our data are consistent with a global state of immune suppression 
in dogs with advanced cancer that is likely attributable to several mechanisms. 
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The practical deliverable of this study is a simple three marker surface 
immunophenotype that can be used to prospectively monitor MDSC burden in 
dogs. We have performed pilot studies to look for additional markers. Specific 
preliminary results that are worth noting are as follows. We have been unable to 
demonstrate successful staining using anti-human CD66b antibodies. CD66b is 
an activation marker expressed on some human MDSC (59). The most widely 
used marker for MDSC in the mouse is Gr-1, and an antibody against mouse Gr-
1 was demonstrated to have cross-reactivity with canine cells, as does anti-
mouse CD11b (Figure S1). Further studies will be required to determine if canine 
cells that are identified by anti-mouse Gr-1 and CD11b antibodies are indeed 
MDSCs. 
One potential limitation of this study that many of the samples we 
analyzed were frozen, the thawed before analysis, which could have influenced 
cell viability. However, freeze-thaw did not significantly affect cell viability of 
either granulocytic or monocytic MDSC (Figure S3). We consider this a positive 
finding because canine MDSCs could be frozen from multiple time points in 
future prospective studies, then thawed and analyzed simultaneously to limit 
batch to batch variability. A second limitation is that the RTPCR analysis of 
immunosuppressive molecules was qualitative, was performed on a small 
number of dogs (Table S3), and was not a direct comparison to matched healthy 
cells. We were not able to obtain adequate viable CD11b+CD14-MHCII- cells from 
healthy dogs by FACS to directly compare to the same population from dogs with 
cancer due to their low frequency and apparently high rate of cell death following 
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FACS. For this reason, normal PMNs isolated by gradient centrifugation were 
used for comparison in our studies. Quantitative mechanistic studies should be 
conducted to dissect which of the candidate molecules studied herein mediate T 
cell suppression.  
Additionally, some of the dogs had received treatment for their cancer. 
This is relevant because MDSC levels in human cancer patients have been 
shown to be influenced by prior therapy. It is also known that tumor burden and 
inflammation significantly affect circulating MDSC levels. Studies in mice have 
shown that accumulation and suppressive activity of MDSCs are regulated by the 
inflammatory milieu (72). Thus treatment, such as surgical excision of the tumor, 
chemotherapy, and nonsteroidal anti-inflammatory drug (NSAID) administration, 
can alter the levels of these cells in the peripheral blood. Evaluation of the 
medical records of dogs in our study revealed that many dogs received some 
therapy prior to blood sample collection, which could have affected the levels of 
MDSCs in these samples (see Tables S1 and 2S). However, Figure S4 
demonstrates that treatment of dogs with advanced cancer did not significantly 
alter MDSC burden relative to dogs that had not been previously treated. 
Therefore, our study provides evidence that expanded MDSCs are likely a 
robust, general feature of cancer in canines despite genetic heterogeneity and a 
range of previous treatments (or lack of previous treatment).  
In summary, we have identified a granulocytic subset of cells with 
immunosuppressive function that are elevated in dogs with advanced cancer that 
can be characterized as MDSCs. Canine MDSCs may be a potential target for 
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therapeutic interventions in dogs with cancer. Furthermore, the study of MDSCs 
in dogs treated with experimental therapies should reveal unique insights into 
what might be expected in human patients. This cross-species comparison 
provides an attractive opportunity to move the field of translational medicine 
forward. 
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Table1. Characteristics of dogs with cancer in the study 
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Table 2. Characteristics of healthy dogs in the study 
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Figure 1. Immunophenotyping gating strategy and morphological analysis 
for MDSC identification in peripheral blood of dogs. PBMCs from healthy 
dogs and dogs with cancer were stained for the myeloid marker CD11b, 
monocytic marker CD14 and MHC II. (A) Representative flow cytometric analysis 
of forward and side scatter and gated CD11b+CD14−MHCII− cells from dogs with 
advanced or metastatic tumors compared to dogs with early stage non-
metastatic tumors and healthy control dogs. Plots are representative of dog with 
advanced metastatic hemangiosarcoma (top), early stage bladder transitional cell 
carcinoma (middle) and a healthy dog. (B) FACS sorted CD11b+CD14−MHCII− 
cells were stained with diff-quick for cell morphology evaluation. A representative 
example of polymorphonuclear granulocyte morphology of CD11b+CD14−MHCII− 
cells is shown at 63× magnification. 
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Figure 2. Percentage of circulating CD11b+CD14−MHCII− cells in dogs with 
cancer correlates with clinical tumor stage. (A) Analysis of average 
CD11+CD14−MHCII− population frequency in dogs with advanced stage or 
metastatic tumors (n = 30) compared with early stage non-metastatic tumors (n = 
15) and control dogs (n = 18). There was a significantly higher percentage of 
CD11b+CD14−MHCII− cells in dogs with advanced cancer versus early stage 
non-metastatic tumors and healthy dogs (36.04% vs. 9.40% and10.24%, 
respectively. B) Average CD11b+CD14−MHCII− population frequency in the major 
cancer subtypes: advanced stage or metastatic sarcomas (n = 18), early stage 
non-metastatic sarcomas (n = 6), advanced stage or metastatic carcinomas (n = 
7) early stage non-metastatic carcinomas (n = 7), advanced stage or metastatic 
mast cell tumors (n = 5) and early stage non-metastatic mast cell tumors (n = 2) 
compared with control dogs (n = 18). Significantly elevated percentages were 
detected in all advanced tumors subtypes relative to early stage tumors and 
healthy dogs. Percentages of CD11b+CD14+MHCII− cells were not significant 
between groups (* indicates P<0.001). Mean ± SEM are shown. 
 
 
 
 
 
 
 
 47 
 
 
Figure 3. CD11b+CD14−MHCII− cells suppress T cell proliferation and 
cytokine elaboration. CD11b+CD14−MHCII− cells were sorted from peripheral 
blood sample of dogs with cancer and then co-cultured with autologous PBMCs 
(A, B) or healthy dog PBMCs (C) in the presence of mitogen for 72 hs. 
Representative examples from a total of eight dogs are shown. The graphs 
represent proliferative responses after addition of CD11b+CD14−MHCII− isolated 
from a single dog with squamous cell carcinoma (3A), prostatic adenocarcinoma 
(3B) and osteosarcoma (3C). Non-stimulated PBMCs were used as negative 
control and PBMCs stimulated in absence of CD11b+CD14−MHCII− cells were 
used as positive control for proliferation. PBMCs were also co-incubated with 
PMNs, to control for presence of additional cells (3C, 3D). Proliferative responses 
were measured by 3H-thymidine incorporation. CPM, counts per minute. Amount 
of IFN-γ secretion in the co-culture was determined using canine specific IFN-γ 
ELISA assay (3D). All experiments were performed in triplicate. Mean ± SEM are 
shown. 
 48 
 
 
Figure 4. CD11b+CD14−MHCII− cells suppress T cell proliferation. 
Facs sorted CD11b+CD14−MHCII− cells isolated from a dog with osteosarcoma 
or healthy PBMCs were co-incubated with mitogen-stimulated CD4+ and CD8+ T 
cells isolated from a healthy dog for 72 hrs. No stimulated cells were used as 
negative control. Proliferative responses were measured by 3H-thymidine 
incorporation from experiments performed in triplicate. CPM, counts per minute. 
Mean ± SEM are shown. 
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Figure 5. CD11b+CD14−MHCII− cells express MDSC-derived 
immunosuppressive factors. 
RT-PCR analysis of FACS purified CD11b+CD14−MHCII− cells detected 
expression of ARG1 and iNOS2, as well TGF-β and IL-10 immunosuppressive 
cytokines. ARG-1 expression was not detected in normal PMNs. 
CD11b+CD14−MHCII− cells were isolated from the peripheral blood of a dog with 
osteosarcoma and PMNs were isolated from a healthy dog. NRT, RNA template 
in the absence of reverse transcriptase. Results are representative three 
experiments. 
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Supporting Information 
 
 
 
Figure S1. Mouse anti-CD11b and Gr-1 antibodies cross-react with canine 
samples. Fresh PBMCs from healthy dog and cancer patients were isolated by 
Ficoll, stained with anti-mouse CD11b and anti-mouse Gr-1 antibodies. 
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Figure S2. CD11b+CD14+MHCII− cells demonstrate ability to suppress T cell 
proliferation. (A) CD11b+CD14+MHCII− cells were sorted from peripheral blood 
sample of an osteosarcoma dog (B) and co-cultured with healthy dog PBMCs in 
the presence of mitogen for 72 hrs. Non-stimulated PBMCs were used as 
negative control and PBMCs co-cultured with healthy PMNs were used to control 
for the effect of adding cells to the assay. Proliferative responses were measured 
by 3H-thymidine incorporation. CPM, counts per minute. The experiment was 
performed in triplicate. Mean ± SEM are shown. 
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Figure S3. Frequency of MDSCs measured was not significantly altered by 
cryopreservation. MDSC percentages in fresh and frozen samples were 
assessed for comparison. Mean ±SEM are shown. 
 
 
 
 
 
 
 
 
 
 
 
 53 
 
Figure S4. No significant effect of pretreatment on MDSC burden. Analysis 
of the average CD11b+CD14−MHCII− population frequency in treated (n = 17) or 
untreated dogs with advanced stage or metastatic tumors (n = 13) compared to 
control dogs (n = 18). There was a significantly higher percentage of 
CD11b+CD14−MHCII− cells in dogs with advanced cancer treated or untreated 
compared to healthy dogs (32.69±3.24%, 40.42±3.86% vs. 10.24±1.412%, 
respectively). N.S., not statistically significant (there was no significant difference 
between samples that had been treated compared to those from untreated 
samples). Mean ± SEM are shown (* indicates P<0.0001). 
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Table S3. Table of canine cancer patient samples and the experiments in 
which the PBMCs were used 
 
 
 
 
 
 
 
Sample Number Experiment (s) Figure (s) 
Sample 3 - Healthy Immunophenotyping 1A 
Sample 5 - Advanced Stage Tcell proliferation, cytospin N.S 
Sample 5 - Healthy Tcell proliferation N.S 
Sample 6 - Advanced Stage Tcell proliferation, RT-PCR 4, 5 
Sample 6 - Healthy Tcell proliferation, RT-PCR 4, 5 
Sample 7 - Early Stage Tcell proliferation, cytokine elaboration,  N.S 
 cytospin  
Sample 8 - Advanced Stage Tcell proliferation, cytokine elaboration,  3C,3D 
Sample 8 - Early Stage Tcell proliferation, cytokine elaboration N.S 
Sample 9 - Early Stage Immunophenotyping 1A 
Sample 10 - Healthy Tcell proliferation, cytokine elaboration N.S 
Sample 10 - Advanced Stage RT-PCR N.S 
Sample 11 - Advanced Stage Immunophenotyping 1A 
Sample 12 - Healthy Tcell proliferation, cytokine elaboration 3C,3D 
Sample 13 - Healthy RT-PCR, Tcell proliferation, cytokine  N.S 
 elaboration  
Sample 14 - Advanced Stage RT- PCR N.S 
Sample 16 - Advanced Stage RT- PCR N.S 
Sample 17 - Healthy RT-PCR N.S 
Sample 18 - Advanced Stage Immunophenotyping S1 
Sample 18 - Healthy Tcell proliferation, cytokine elaboration N.S 
Sample 19 - Advanced Stage Tcell proliferation 3A 
Sample 20 - Advanced Stage Tcell proliferation 3B 
Sample 22 - Advanced Stage Cytospin 1B 
Sample 23 - Advanced Stage RT- PCR N.S 
Sample 29 - Advanced Stage RT-PCR, cytospin N.S 
Sample 30 - Advanced Stage Tcell proliferation, cytokine elaboration  N.S 
 cytospin  
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Table S4. Primer sequences for genes evaluated by semi-quantitative PCR 
 
Gene   Primer Sequence (5'-3') Size 
IL-10 Forward GTCCCTGCTGGAGGACTTTAAGA 443 bp 
 Reverse TGGTCGGCTCTCCTACATCTCG  
ARG-1 Forward TGGCCTGCTGGAGAAACTTA 190 bp 
 Reverse CAGCACCAGGCTAGTCCTTC  
INOS-2 Forward AAGTCCAAGTCTTGTCTGGGAGC 185 bp 
 Reverse TCCTTTGTTACTGCTTCCACCCT  
TGF-β Forward AGTTAAAAGCGGAGCAGCATGTGG 434 bp 
 Reverse GATCCTTGCGGAAGTCAATGTAGAGC  
β-actin Forward CCAGCAAGGATGAAGATCAAG 100 bp 
 Reverse TCTGCTGGAAGGTGGACAG  
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Summary 
 
Glioma is a very aggressive and devastating malignancy of the brain that 
is associated with a dismal prognosis despite the use of aggressive standard 
treatment protocols. The poor prognosis for patients with high-grade glioma has 
led to the development of various immunotherapeutic strategies to induce 
specific immune response against the malignant tumors. Despite encouraging 
preclinical results, successful responses in human clinical trials have not been 
achieved in part due to tumor-induced immunosuppression. Systemic 
immunosuppression and elevated percentages of circulating and tumor-infiltrating 
MDSC have been reported in patients with malignant gliomas. 
Similar to that in humans, malignant glioma in dogs is a disease with very 
dismal prognosis and survival. Due to the similarities between canine and human 
gliomas, we hypothesized that gliomas in dogs would demonstrate the same 
pattern of immunosuppression observed in humans. Therefore we assessed the 
percentage of MDSC in the peripheral blood of dogs with glioma. 
Our results demonstrated that dogs with glioma have elevated 
percentages of circulating CD11b+CD14+MHCII- cells and elevated levels of 
serum arginase activity compared to control dogs without glioma. Moreover, 
increased percentages of CD11b+CD14+MHCII- cells were detected in all of the 
glioma subtypes analyzed including GBM, oligodendroglioma and astrocytoma. 
Importantly, we also evaluated the anti-mouse Gr-1 antibody as a potential 
marker of MDSC in dogs and the results of flow cytometry analysis and IHC 
 60 
staining demonstrated that the anti-mouse Gr-1 antibody is not suitable for 
canine species. 
 
Introduction 
Glioma is a very aggressive and devastating malignancy of the brain that 
is associated with dismal prognosis. Despite the use of aggressive therapeutic 
regimens, median progression-free and survival times remain poor and a cure is 
still elusive. One hurdle in treating malignant brain tumors is the highly 
immunosuppressive microenvironment that favors the rapid spread of the glioma 
cells into the normal brain tissue (104).  
The standard of care therapy for malignant gliomas involves surgical 
excision followed by radiation and chemotherapy. Nevertheless, surgical 
resection cannot completely eliminate the profusion of infiltrating neoplastic cells. 
Radiation and chemotherapy affect normal cells in addition to the cancer cells 
they target and have other limitations, such as the development of resistance by 
the tumor.  
The poor prognosis for patients with high-grade glioma has led to the 
development of new therapeutic strategies, such as immunotherapy designed 
specifically to engage the immune system to recognize and attack the tumor cells 
(105, 106). Several studies have been developed to stimulate tumor-specific T 
cell responses in murine preclinical models (107-111). However, despite the 
relative safety and exciting preclinical results immunotherapeutic approaches 
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have shown, effective anti-tumor immunity against malignant gliomas has not 
been generated in the clinical setting (106, 112).  
It is clear now that immunogenicity is not sufficient for generation of 
effective antitumor responses, and the negligible improvement in survival of 
patients treated with immunotherapeutic approaches is likely due an inability to 
successfully overcome tumor-induced immune suppression (105, 111, 112).  
Systemic immunosuppression and defective Tcell immune responses in 
patients with malignant gliomas are well-documented (113), and significantly high 
percentages of circulating (50, 114) and tumor-infiltrating MDSC have been 
recently reported (63).  
Similar to that in humans, dogs develop spontaneous brain tumors that 
carry a very poor prognosis regardless of therapeutic intervention. Due to the 
genetic, biologic and histological similarities between human and canine glioma, 
and the fact that these tumors evolve over long periods of time, interacting 
dynamically with an immunocompetent host, it is possible that canine glioma 
recapitulates the same mechanisms of resistance observed in human disease (1, 
115). Therefore, the examination and quantification of the immune suppressive 
components in dogs with glioma may provide valuable information of the 
immunological status of these dogs and offer new insights into why some 
immunotherapies fail to induce an antitumor response and elicit survival benefit. 
Given prior observations of T cell dysfunction and the documentation of 
elevated percentages of immunosuppressive myeloid cells in glioma patients, the 
objective of the present study was to evaluate MDSC accumulation in the 
 62 
peripheral blood of dogs with glioma using the combination of the three surface 
markers CD11b, MHCII and CD14. In addition, we investigated the use of anti-
mouse Gr-1 antibody as a potential marker of MDSC in dogs.  
 
Materials and Methods 
Patient Population 
Blood samples from 26 canine patients diagnosed with glioma and 10 h 
control dogs without glioma were included in the study. Control dogs were 
determined to be healthy based on owner observations and a complete physical 
examination by a veterinarian. Analysis was performed using blood samples from 
dogs with newly diagnosed glioma prior to any definitive cancer treatment. All of 
the canine glioma patients included had a presumptive diagnosis of glioma based 
on MRI characteristics as well as a definitive histological diagnosis from biopsy 
tissues by a team of experienced neuropathologists. Blood samples were 
collected at the University of Minnesota Veterinary Medical Center after obtaining 
owner consent according to an approved protocol from the Institutional Animal 
Care and Use Committee guidelines.  
 
Peripheral Blood Mononuclear Cells Isolation  
Peripheral blood of dogs diagnosed with glioma and healthy donors were 
collected in heparinized tubes for peripheral blood mononuclear cells (PBMCs) 
isolation. Briefly, blood was diluted 1:3 with sterile phosphate-buffered saline 
(PBS, Invitrogen) and layered over lymphocyte separation medium (Cellgro). 
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Samples were centrifuged at 400 x g for 30 min. PBMCs were collected from the 
interface, transferred to a fresh tube and washed twice in PBS. Cells were 
resuspended in freeze medium containing 10% DMSO (Sigma) in FBS 
(Invitrogen) and stored in liquid nitrogen. For phenotypic studies, PBMC samples 
from the canine patients with gliomas were thawed for 2 minutes in a 37°C water 
bath before being stained with antibodies and analyzed by flow cytometry. 
PBMCs collected from the control dogs were isolated as described above but 
rather than storing frozen, were resuspended in FACS buffer, stained with 
antibodies and immediately analyzed by flow cytometry. 
 
Serum samples 
Peripheral blood of dogs with glioma was collected into red-topped clotting 
tubes for serum isolation. The blood tubes were centrifuged at 2500 x g for 5 min, 
the serum was decanted, 200 µl aliquots were placed into cryovials and stored in 
a -80°C freezer. 
 
Flow Cytometric Analysis of patient PBMCs  
For the analysis of patient PBMCs for MDSC, samples were thawed, 
washed in RPMI and resuspended in FACS buffer. Non-specific antibody binding 
was blocked by pretreatment of cells with 10mg/mL of canine gamma-globulin 
(Jackson Immunoresearch) for 20 min at room temperature. Cells were stained 
with anti-mouse PE conjugated CD11b (clone M1/70 eBioscience), anti-human 
Alexa fluor 647-conjugated CD14 (clone TU¨ K4, AbD Serotec) and the anti-dog 
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FITC-conjugated MHCII (clone YKIX334.2, AbD Serotec) at 4°C for 30 min in a 
dark room according to the manufacturer’s protocol. Stained cells were washed 
twice, resuspended in FACS buffer, and incubated for 10 minutes at room 
temperature in the dark with 7AAD (BD pharmingen) before analysis by flow 
cytometry. Results are expressed as the percentage of positive cells of the total, 
live-gated PBMC. Data were acquired using BD FACS Diva LSRII instrument and 
analyzed using FlowJo software (Tree Star).  
 
Arginase activity assay 
Arginase was measured using a chromogen arginase assay kit (Abnova). 
Briefly, serum samples were thawed, diluted at 1:5 in PBS, mixed with substrate 
buffer and manganese solution and incubated for 2h at 37°C. Following the 
addition of urea reagent, samples were incubated at room temperature for 
another 20min. Optical density (OD) was measured at a wavelength of 530nm in 
an iMark Microplate Reader (Bio-Rad). Arginase activity was calculated using the 
formula [OD sample - OD blank / OD standard – water x 10.4x dilution] Urea 
solution (1M) was used as the standard. Arginase activity was expressed as units 
per liter. 
 
Gr-1 antibody staining and cell isolation  
For functional analysis, fresh blood samples from tumor-bearing dogs 
were used for isolation of Gr-1+ cells. Cells were magnetically labeled and 
isolated using the Myeloid-Derived Suppressor Cell Isolation Kit and LS magnetic 
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columns (Miltenyi Biotech) in accordance with the manufacturer’s instructions. 
For flow cytometry analysis, samples were stained with anti-mouse PE 
conjugated CD11b (clone M1/70 eBioscience) and anti-mouse APC-conjugated 
Gr-1 (clone RB6-8C5 eBioscience) antibodies or isotype controls at 4°C for 30 
min in a dark room according to manufacturer’s protocol. 
 
Ex Vivo Proliferation  
PBMCs from dogs with glioma and control dogs were first labeled using 
CellTrace Violet Cell Proliferation Kit (Invitrogen Molecular probes) according to 
the manufacturer’s instructions and seeded into U-bottom 96-well plates 
(1×105cells/well) in RPMI 1640 medium containing L-arginine (150 µM) 
(Invitrogen) supplemented with penicillin/streptomycin (Invitrogen) and 10% heat-
inactivated fetal bovine serum (Invitrogen) at 37°C in a 5% CO2 incubator. Cells 
stained with Gr-1 antibody were isolated from dogs with cancer as previously 
described and added at a ratio of 2:1 to cancer (autologous) or healthy responder 
PBMCs. Concanavalin A (2µg/ml) (Sigma) was used to stimulate T cell 
proliferation. Non-stimulated PBMCs were used as negative control. Proliferation 
of T cells was assayed by flow cytometry of dilutions of the CellTrace dye after 
72hrs in culture. Acquired data were analyzed using FlowJo (Tree Star). 
 
Immunohistochemistry (IHC) 
For analysis of Gr-1 expression in canine tissues, 4µm formalin-fixed, 
paraffin-embedded sections of tissue were deparaffinized and rehydrated, 
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followed by pepsin treatment for 15 minutes at room temperature.  
Immunohistochemistry for Gr-1 was performed on a Dako Autostainer using rat 
anti mouse Gr-1 monoclonal antibodies (1A8 and RB6-8C5 clones) as the 
primary antibody (after blocking endogenous peroxidase and application of a 
protein block), detected using a rat-on-mouse HRP-polymer kit (Biocare) with 
diaminobenzidine (Dako) as the chromogen.  Mayer’s hematoxylin (Dako) was 
used as the counterstain. To verify the cross-reactivity of the anti-mouse Gr1 
monoclonal antibodies on canine tissues, canine bone marrow and lymph nodes 
were stained as test tissues. Mouse spleen was used as the positive control 
tissue, whereas for the negative control, the primary antibody was substituted 
with rat serum (Biogenex).   
 
Statistical analyses 
Statistical analysis was performed using GraphPad Prism v5.0 
(GraphPad). The differences between two groups were analyzed using Mann-
Whitney test. P values <0.05 were considered to be statistically significant. 
 
Results 
Characteristics of the patients in the study 
Blood samples from 26 dog patients with newly diagnosed glioma and 10 
healthy controls were analyzed in the study. The average ages of dogs with 
glioma and healthy control dogs were 7.6 years and 6.8 years, respectively. 
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Boston terriers and Boxers accounted for 54% of the gliomas patients. Among 
the 26 dogs diagnosed with glioma, there were 11 dogs with glioblastoma 
multiforme (GBM), 6 dogs with high-grade oligodendroglioma, 4 dogs with 
anaplastic astrocytoma, 2 dogs with grade II astrocytoma, and 1 dog each with 
unspecified high-grade glioma, unspecified low-grade glioma and low-grade 
oligodendroglioma (Table1). 
 
Dogs with glioma have elevated levels of CD11b+CD14+MHCII- cells 
Blood samples from dogs with glioma and healthy controls were evaluated 
by flow cytometry for quantification of the percentages of MDSC. Gating strategy 
for analysis of granulocytic and monocytic subsets of MDSC is shown in Fig 1. 
A significantly increased percentage of circulating CD11b+CD14+MHCII- 
cells was observed in the blood of glioma patients compared with health control 
dogs (P=0.0001) (Fig 2). Although not significant, the percentage of 
CD11b+CD14-MHCII- cells was also elevated. The significant increase in 
CD11b+CD14+MHCII- cells in the blood of glioma dogs compared with control 
dogs differs with the findings of our previously published canine MDSC study. In 
the previous study we detected significant increases in CD11b+CD14-MHCII- cells 
in the blood of dogs with advanced sarcomas, carcinomas and mast cells tumors 
relative to healthy controls but no significant differences in the 
CD11b+CD14+MHCII- population (116) . 
We next determined whether there were differences in the percentage 
distribution of the two MDSC subsets among the subtypes of glioma. For this 
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analysis we grouped the glioma samples into 3 histological subtypes: GBM (11 
dogs), oligodendrogliomas (n=7), astrocytomas (n=6). Two dog samples from the 
previous analysis were not included in this evaluation because there was no 
determination of specific subtype. We observed that the percentages of the 
monocytic MDSC subset were significantly increased in all of tumor subtypes, 
GBM (P=0.0008), oligodendroglioma (P=0.007) and astrocytoma (P=0.017) 
compared to healthy controls (Fig 3). The granulocytic population was also 
elevated comparing to healthy dogs, but only dogs with oligodendroglioma had a 
significant increase (P=0.0136). These results indicated that dogs with glioma 
tumors were unique relative to dogs with other types of solid tumors that have 
been examined with regard to their increase in percentage of the monocytic 
MDSC population.  
 
Dogs with glioma have elevated levels of serum arginase1 
It is known that MDSC can effectively suppress tumor-specific T 
lymphocyte function by secretion of soluble factors such as the enzymes ARG1 
and iNOS2 (39, 41-43, 54, 73, 77, 92, 95). Excessive amounts of ARG1 rapidly 
reduce L-arginine from the microenvironment and profoundly impair T cell 
proliferation and function. Since elevated serum arginase activity has been 
documented in patients with several types of cancer including gliomas (50, 59, 
62, 114), we sought to evaluate whether elevated levels of arginase would also 
be present in the serum of dogs with glioma. Our results demonstrated that, like 
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that in humans, dogs with glioma have significantly elevated serum arginase 
activity, possibly due to the greater number of CD11b+CD14+MHCII- cells (Fig 4).  
 
 
 
Gr-1 marker in canine cells 
MDSCs in mice are characterized by the expression of both myeloid cell 
markers Gr-1 and CD11b. Although there is no commercially available anti-
canine Gr-1 antibody Krol et al study demonstrated that anti-mouse Gr-1 
antibody was capable to stain metastatic canine mammary carcinoma tissues 
(117). In a previous study, we reported that anti-mouse Gr-1antiboby stained 
canine PBMCs, however we did not validate whether the anti-mouse Gr-1 
antibody would specifically stain and identify canine MDSC (116). To address this 
question, we performed functional assays, immunophenotyping and 
immunohistochemistry analysis. First, we evaluated the ability of the cells stained 
with Gr-1 antibody to inhibit proliferation of responder PBMCs following 
stimulation with ConA. Since we did not have fresh glioma PBMC samples 
available at the time of this analysis, we used peripheral blood samples from 
dogs with transitional cell carcinoma and hemangiosarcoma for functional 
experiments. Our results demonstrated that cells isolated with Gr-1 magnetic 
beads from a dog with hemangiosarcoma inhibited proliferative responses of 
autologous and health responders (Fig 5). However, although our results 
demonstrated that cells isolated from a cancer patient efficiently suppressed 
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PBMCs proliferation, we observed that the magnetic isolation of cells stained with 
Gr-1 antibody was not very efficient and only small number of cells were being 
recovered after positive selection. Based on those results, for immunophenotype 
analysis we stained canine glioma PBMCs with CD11b and Gr-1 antibodies or 
isotype controls in the presence or absence of dog gamma-globulin pre-
treatment for non-specific antibody blocking. Of note, pre incubation with dog 
gamma-globulin was not done prior to magnetically labeling the cells. We 
observed that antibody blocking completely abrogated anti-mouse Gr-1 antibody 
binding (Fig 6A) on canine cells.  
To verify the binding and cross-reactivity of the Gr-1 in canine tissues we 
used canine bone marrow and lymph node tissue samples, and mouse bone 
marrow as a positive control. As expected, mouse bone marrow stained 
positively for Gr-1, however none of the canine tissues were positive for Gr-1, 
results that differ from those observed by Krol et al. that showed positive mouse 
Gr-1 antibody staining in canine tissues (117). 
We conclude from these results that there is indeed a population of cells 
capable to suppress immune T cell function in the peripheral blood of dogs with 
cancer, however anti-mouse Gr-1 antibody is not an appropriated antibody to 
identify this population of cells. An possible explanation for this finding is that 
anti-mouse Gr-1 antibody bound in a nonspecific manner to canine cells which 
allowed us to isolate a small fraction of cells from the PBMC pool. However, due 
to a weak nonspecific binding to canine epitopes, the isolation procedure was not 
optimal. 
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Discussion 
Tumor-induced immune suppression is a condition that accompanies 
tumor progression and occurs in many patients with cancer. Myeloid-derived 
suppressor cells (MDSC) have emerged as key suppressors of tumor specific T-
cell responses in various tumor models and human malignancies becoming the 
focus of intense study. However MDSC in dogs have not been extensively 
characterized, so limited information is available.  
In this study, we have examined circulating MDSC in 26 canine glioma 
patients identifying the phenotypes CD11b+CD14-MHCII- for granulocytic and 
CD11b+CD14+MHCII- cells for monocytic MDSC, as described in our previous 
study (116). Contrary to the earlier findings, in dogs with a variety of solid tumors, 
these results showed that dogs with malignant glioma have significantly 
increased numbers of the CD11b+CD14+MHCII-cells, which we identified as the 
monocytic MDSC population, compared with healthy controls. Moreover, the 
increase was consistent elevated in all of the glioma subtypes analyzed in the 
study. Importantly, although we did not observe significant increases in this cell 
population in the peripheral blood of dogs with solid tumors in our previous study, 
CD11b+CD14+MHCII-cells sorted from those dogs demonstrated ability to inhibit 
T cell proliferation (116). We also observed an increase in the granulocytic 
subset CD11b+CD14-MHCII- cells, however, this increase was significant only in 
the dogs with oligodendroglioma. It is possible that specific tumor types may 
uniquely upregulate specific MDSC subsets, perhaps by secretion of tumor 
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derived-factors (43).  
The human monocytic CD11b+CD14+HLA-DR-/lowcells have been identified 
in various human malignancies such as, melanoma, hepatocellular carcinoma, 
head and neck squamous cell cancers (HNSCC) and glioblastoma (63, 80, 118, 
119). Additionally, correlation between expression of IL-4R and suppressive 
activity in the monocytic MDSC population has been documented in colon, 
melanoma and glioblastoma cancers (63, 84). Dunddel et al. demonstrated that 
the CD11b+CD14+HLA-DR-/lowcells elevated in HNSCC patients displayed 
predominantly mononuclear features, expressed CD33 and CD34 markers and 
high levels of pSTAT3, ARG1 and ROS. Moreover, although this cell population 
was elevated in the peripheral blood, lymph nodes and tumor tissues from 
patients, with higher percentages observed in the tumor tissue and they have the 
ability to secrete ARG-1 and suppress T cell proliferation (119). Hoechst et al. 
showed that immune suppression by CD14+HLA-DR-/lowcells was mediated 
through arginase activity and the induction of T Reg cells.  
 Kohanbash and colleagues recently demonstrated that myeloid cells 
heavily infiltrate malignant gliomas and the tumor microenvironment contains 
high levels of GM-CSF, which induces the differentiation of immature myeloid 
cells into ARG1-producing MDSCs via IL-4Rα signaling (63, 120). Furthermore, 
these cells express higher levels of TGF-β, ARG-1 and COX-2 and efficiently 
suppress the proliferation of autologous CD8 T cells and IFN- γ production (63). 
Rodrigues et al. demonstrated that normal human monocytes exposed to glioma 
cell-conditioned media acquire myeloid-derived suppressor cell-like properties 
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(121). However, elevated percentages of the lineage negative, CD33+ HLA-DR- 
and granulocytic CD33+ HLA-DR-CD15- MDSC, have been found in the 
peripheral blood of patients with glioblastoma (50, 121).  
In the present study we found significant increases in arginase activity in 
the serum of dogs with gliomas compared with healthy controls. Therefore we 
proposed that the increased arginase activity in these patients, could be due to 
the increased numbers of CD11b+CD14+MHCII- cells in peripheral blood 
samples, as was observed in human MDSC studies (63, 80, 118, 119). Although 
our current understanding of human MDSC is primarily derived from peripheral 
blood analysis, studies have evaluated the MDSC populations in human tumor 
tissues and compared them results from these studies indicate that the 
percentages of tumor infiltrating monocytic MDSC significantly differ from the 
peripheral blood. Kohanbash et al. demonstrated that infiltrating CD14+HLA-DR- 
IL-4α monocytes are significantly elevated in the patient GBM tissues compared 
to circulating PBMCs (63). Comparable results were also found in HNSCC 
patients, where significantly percentages of CD14+HLA-DR- cells were found in 
tumor tissue and lymph nodes compared with peripheral blood (119). While 
isolation and phenotyping of tumor-infiltrating MDSC were beyond the scope of 
our study, since there was an increase of CD11b+CD14+MHCII-cells in peripheral 
blood of glioma dogs (Fig 2), cells with similar phenotype may also be elevated in 
the tumor microenvironment.  
Although we demonstrated that both CD11b+CD14-MHCII- and 
CD11b+CD14+MHCII- cells were endowed with suppressive capabilities in 
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peripheral blood of dogs with advanced sarcomas and carcinomas (116), we 
acknowledge that is it important to evaluate and confirm the immunosuppressive 
function of these cells in the context of brain tumors. MDSC phenotypes and 
suppressive function are likely to depend on tumor-derived factors in the tumor 
microenvironment, different tumor types could induce the accumulation of 
different cell subsets.  
We were unable to reliably analyze the immunosuppressive function of 
CD11b+CD14+MHCII- cells in this study because all of the patient samples 
evaluated were obtained from cryopreserved PBMCs. It is known that blood 
sample processing and cryopreservation can affect the viability of various blood 
cells, so functional studies of MDSC should always be performed in fresh blood 
samples. A recent study demonstrated that cryopreservation significantly 
impaired MDSC suppressive function and affected the frequency of MDSC 
subsets in human samples (122). MDSC that were thawed after cryopreservation 
completely lost the ability to suppress autologous T cells and to express the 
immunosuppressive markers ARG-1 and ROS. In addition, the granulocytic 
subset of MDSC was shown to be quite sensitive to the freeze-thaw procedure, 
while the monocytic appear to not be affected. Therefore it is possible that the 
frequency of MDSC, and in particular G-MDSC, may be underestimated during 
retrospective clinical analyses using frozen blood samples due to the sensitivity 
of this subset to cryopreservation (123). 
 Interestingly, we did not appreciate significant increases in the 
granulocytic subsets of MDSC in our canine glioma patients with the exception of 
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those diagnosed with oligodendroglioma. Therefore, further investigation is 
needed to determine if the reason for low numbers of G-MDSC in our canine 
glioma patients is due to the selective impact of cryopreservation on the viability 
and recovery of these cells or to intrinsic tumor-derived factors that preferentially 
select for M-MDSC.   
We also investigated whether the anti-mouse Gr-1 antibody would cross-
react with and be used to identify to immunosuppressive MDSC populations in 
dogs. Contrary to the results of Krol et al (117) our results demonstrated that 
anti-mouse Gr-1 antibody failed to specifically stain canine cells and tissues. 
In conclusion, we found a significant increase in the frequency of cells with 
the CD11b+CD14+MHCII- phenotype in the peripheral blood of dogs with glioma, 
as well, elevated serum arginase activity. On the basis of these findings we 
proposed that CD11b+CD14+MHCII cells might represent the major 
immunosuppressive MDSC population in canine glioma patients. Further 
investigations using fresh blood are required to assess the immunosuppressive 
function of MDSCs and to determine whether the granulocytic subset, 
CD11b+CD14-MHCII- is elevated in the peripheral blood of canine glioma 
patients.  
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Table 1. Summary data of dogs in the study 
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Figure 1. Flow cytometry analysis of circulating MDSC in dogs with glioma. 
PBMCs from healthy control dogs and dogs with glioma were stained with 
CD11b, MHCII and CD14 antibodies. Forward and side scatter gate was 
analyzed for CD11b+ cells. Positive CD11b gate was then analyzed by the 
expression of MHCII and CD14 markers. Top panels are representative of 
healthy dog while lower panels represent dog with anaplastic astrocytoma. 
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Figure 2. Dogs with glioma have significant increased percentage of 
CD11b+CD14+MHCII- cells.  
Analysis of CD11b+CD14-MHCII- and CD11b+CD14+MHCII- subset percentages 
in glioma patients and healthy controls. A significantly higher percentage of 
CD11b+CD14+MHCII- cells were present in the peripheral blood of dogs with 
glioma. (** indicates P<0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
Figure 3. Percentage of CD11b+CD14+MHCII- cells is significantly increased 
in all of the glioma subtypes.  
On the left side of the graph, analysis of the percentages of CD11+CD14−MHCII− 
cells in the peripheral blood of dogs with GBM, oligodendroglioma and 
astrocytoma compared to healthy dog controls. On the right, analysis of the 
percentages of CD11+CD14+MHCII− cells in the peripheral blood of dogs with 
GBM, oligodendroglioma and astrocytoma compared to healthy dog controls A 
significantly higher percentage of CD11b+CD14+MHCII− cells were detected in all 
of the glioma subtypes, GBM (P<0.0008), oligodendroglioma (P<0.0007) and 
astrocytoma (P<0.0017) compared to controls. 
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Fig 4. Dogs with glioma have elevated serum arginase activity. Analysis of 
serum arginase activity in healthy control dogs and canine glioma patients. 
Serum samples from canine glioma patients had a significantly higher level of 
arginase activity than healthy controls dogs. (P=0.012).  
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Fig 5. Cells isolated with Gr-1-magnetic coated beads inhibit T cell 
proliferation in health PBMCs and autologous PBMCs. 
Cells were magnetically isolated with Gr-1 beads from peripheral blood sample of 
dog with HSA and then co-cultured with both autologous or healthy PBMCs 
labeled with violet dye in the presence of ConA for 72 hrs. Non-stimulated 
PBMCs were used as negative control. Proliferative responses were measured 
by dilution of the dye after 72 hrs in culture. The experiment was performed in 
duplicate. 
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Fig 5. Anti-mouse Gr1 antibody binding of canine PBMCs is non-specific. 
Representative plots of canine glioma PBMCs after stained with CD11b and Gr1 
antibodies or isotype controls with and without canine gamma globulin pre-
treatment as antibody blocking. Top panel - cells stained with isotype control. 
Lower panel - test sample. 
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Fig 5. Anti-mouse Gr1 antibody failed to cross-react with canine tissues. 
IHC analysis of mouse bone marrow (top) canine bone marrow (lower left) and 
lymph node tissue samples (lower right) stained with anti-mouse Gr-1 antibody. 
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Rationale 
The study of naturally cancer in pet animals with the comparison to its 
human counterpart to identify promising treatments that can benefit both humans 
and animals has greatly increased in the past few years. Due to several 
similarities with human cancers and the ability to employ comparable therapeutic 
modalities, spontaneous cancers in companion animals are suited to uniquely 
contribute to the understanding of cancer pathogenesis, tumor biology and 
progression, and evaluation of new drugs and therapies (1, 3, 5). Therefore pet 
dogs with spontaneous cancers constitute a meaningful preclinical model for 
testing novel immunotherapeutic approaches and are considered outstanding 
platform for translational research. 
The exceptional power of the immune system to identify and destroy 
specific targets has led to the development of a wide variety of immune-based 
approaches to treat cancer. However, multiple immunosuppressive mechanisms 
exist that considerably dampen antitumor responses and weaken the activity of 
current immunotherapeutic regimens (25, 105, 111). Abnormal accumulations of 
myeloid derived suppressor cells in cancer patients produce a profound, global 
immune suppression that significantly interferes with antitumor immunity and 
consequently impairs the efficacy of immune-based therapies. Therefore, 
development of effective immunotherapy for both humans and dogs will benefit 
from further understanding of the mechanisms that drive MDSC expansion and 
function in these patients.  
Although an extensive amount of research has been done to identify and 
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target MDSC in human cancer patients and rodent model of disease (40, 49, 50, 
57, 59-61, 63, 74, 81, 82, 84, 95, 124), research for clinical veterinary patients is 
still in its infancy. To date, in addition to our publication there are only two other 
studies describing potential markers to identify MDSC in dogs. Sherger et al. 
showed that the CD11blow CADO48Alow cell population was significantly 
increased in the peripheral blood of dogs with a variety of tumors, including 
sarcomas, carcinomas, and melanomas, and that these cells were able to 
suppress lymphocyte proliferation in vitro (125). Krol et al. identified myeloid 
precursor cells by immunohistochemistry using the anti-mouse Gr-1 cell surface 
marker in metastatic and non-metastatic mammary carcinomas tissue samples 
from dogs (117). 
Primary studies in humans documented that MDSC could be identified by 
double negative labeling for MHCII molecules and any other surface markers of 
mature lymphoid or myeloid cells, such as CD3, CD19, CD56, CD14 or Lin-/low. 
Further analysis revealed that the double negative population, Lin-/low HDLA-DR- 
also express the myeloid markers, CD33 and CD11b (52). Based on this 
knowledge from human studies, as well as the lack of availability of canine-
specific reagents, we decided to use CD11b, CD14 and MHCII surface markers 
to identify circulating MDSC in canine cancer patients. 
 
Summary of Critical Findings 
1. MDSC accumulate in tumor-bearing hosts. This finding has been 
extensively reported by several others in mouse tumor models, as well as 
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in human patients, where an increased frequency of heterogeneous 
populations of myeloid cells with variable phenotypes have been detected. 
We have found significantly elevated percentages of CD11b+CD14-MHCII- 
cells of the total PBMCs of canine patients with advanced cancer 
compared to those with early stage, non-metastatic tumors or healthy 
controls without cancer. Thus we demonstrated that this myeloid cell 
population accumulates in the peripheral blood of dogs with cancer, and 
also positively correlates with tumor burden. Our results corroborate 
published human studies that correlate increased numbers of circulating 
MDSC correlate with cancer stage and metastatic tumor burden (52). 
Moreover, this elevated population was consistent among the all tumor 
types analyzed, sarcomas, carcinomas, and mast cell tumors. 
 
2.  CD11b+CD14-MHCII- cells exhibit granulocytic morphology and co-
purify with PBMCs. Granulocytic MDSCs in humans were originally 
defined as granulocytic cells that are enriched in the PBMC fraction 
through density gradient separation, and commonly express CD15 and 
CD66b markers. Cytospin analysis of sorted CD11b+CD14-MHCII- cells 
isolated from PBMC layer of blood sample from dogs with cancer showed 
granulocytic morphology that resemble neutrophils, which corroborates 
human studies. In renal cell carcinoma patients, Rodriguez et al. (59) 
demonstrated that MDSC share CD15+ marker expression with normal 
neutrophils, but are less dense, which allows them to co-purify with 
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lymphocytes. Others have identified this population as having the 
phenotype CD33-MHCII- CD14-CD15+ (60) or CD11b+CD14- (40). Despite 
the unavailability of canine-specific CD33, CD15 and CD66b antibodies to 
phenotype our canine MDSC population, we hypothesized that the 
granulocytic MDSC subset could be identified by the combination of 
CD11b+CD14-MHCII- markers. We confirmed that these cells had a 
granulocytic morphology by microscopic analysis. 
 
3.  CD11b+CD14-MHCII- cells suppress T cell proliferation and cytokine 
secretion.  Consistent with human and mice literature, our putative canine 
MDSC population, characterized by the three-marker phenotype are 
endowed with high immunosuppressive activity. The phenotype of the 
granulocytic subset is CD11b+CD14-MHCII- and of the monocytic subset is 
CD11b+CD14+MHCII-.  Our in vitro results demonstrated that the 
CD11b+CD14-MHCII- subset of cells inhibited the proliferation of T 
lymphocytes from autologous responders in a dose-dependent manner. It 
is well known that cancer patients have an impaired ability to respond to 
mitogen stimulation. Therefore we further evaluated the ability of these 
cells to suppress the proliferation of, and cytokine secretion by PBMCs 
collected from control dogs without cancer. Again, addition of 
CD11b+CD14-MHCII-cells impaired T cell function that substantiates the 
immunosuppressive capacity of these cells. Moreover, although we have 
focused on the characterization of the granulocytic MDSC subset, we had 
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also conducted functional experiments with the putative monocytic MDSC 
subset, CD11b+CD14+MHCII-. We demonstrated a robust ability of these 
cells to suppress T cell proliferative responses even though this is not the 
most prevalent subset in peripheral blood.  
 
4. CD11b+CD14-MHCII- cells express hallmark MDSC-derived factors. 
Many immunosuppressive strategies by which MDSC inhibit the 
effectiveness of immune responses have been established. Up-regulation 
of ARG1, iNOS and ROS have been implicated as a major mechanism 
responsible for the immune suppressive activity of MDSC (40, 41, 59, 62, 
92, 95, 119). Increased secretion of immunosuppressive cytokines TGF-β 
and IL-10, and induction of Treg development are indirect mechanisms of 
MDSC immune suppression (39, 54, 73, 80). In support of these findings 
we herein reported that the expression of ARG-1 and iNOS2, as well as 
the immunosuppressive cytokines, TGF- β and IL-10, were detected by 
PCR analysis in CD11b+CD14-MHCII- cells sorted from peripheral blood 
of canine cancer patient. Due to the small percentage of monocytic 
CD11b+CD14+MHCII- cells, we were not able to sort sufficient numbers of 
cells for RNA isolation, therefore quantitative PCR analysis of this 
population could not be carried out. 
 
5.  CD11b+CD14+MHCII- cells are prevalent in the peripheral blood of 
dogs with glioma. Despite observing the accumulation of G-MDSC, 
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CD11b+CD14-MHCII- cells, in the peripheral blood of dogs with glioma, the 
monocytic (CD11b+CD14+MHCII-) subset was also significantly elevated. 
Moreover, the percentage of CD11b+CD14+MHCII- cells was consistently 
high in all of subtypes of glioma analyzed. Besides that the data for M-
MDSC in dogs with glioma differs from that observed in other canine 
tumor types, accumulations of monocytic CD14+ (87), CD14+HLA-DR- (80, 
118) and CD14+IL4Rα+ (63, 84, 120) have been described in several 
human cancers including melanoma, glioblastoma, colon carcinoma and 
HNSCC. Although a glioma-specific phenotype of MDSC has not been 
clearly defined, there is strong evidence that supports increased numbers 
of the monocytic population. Kohanbash et al. have reported 
CD14+IL4Rα+ as the predominant MDSC population in human GBM 
tissues (63) and Gustafson et al. identified an expanded population of 
MDSC with the phenotype CD14+HLA-DR-/low in steroid-treated GBM 
patients (126). Intriguingly, in our study all of canine patients from whom 
we collected blood for MDSC analysis had been previously treated with 
corticosteroids. Conflicting results with higher percentages of granulocytic 
MDSC subsets with the respective phenotypes CD11b+CD33loCD14-HLA-
DR- and CD33+CD15+CD14-HLA-DR- have been demonstrated in some 
GBM patients (50, 114). This data shows that phenotype of MDSC in 
human glioma may not be constant and needs to be further clarified. It is 
also possible that disregulated secretion of certain tumor-derived factors 
by gliomas induce the accumulation of different MDSC subsets. 
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In our analysis of canine glioma patients, elevated but not 
significantly different, percentages of the granulocytic subset were 
observed. Of note, the canine glioma patients’ PBMC samples we used 
had been frozen, and the viability of the granulocytic subset may be more 
susceptible to freezing resulting in an underestimation of their numbers 
(122, 123). In our previous study, we analyzed both fresh and frozen 
samples from canine cancer patients and healthy control dogs, and .we 
were able to detect elevated percentages of G-MDSC in the cancer 
patients compared to health controls in both fresh and frozen samples. 
However, we did observe a slight, but insignificant, decrease in the 
percentage of G-MDSC from frozen samples compared to fresh samples. 
Importantly, samples in our published canine MDSC study were frozen no 
more than 7 days before flow cytometry, while in our canine glioma study, 
samples were frozen for months, or in some cases, years before thawing 
and analysis which may have a greater impact on the viability of certain 
cell subsets. Therefore, in order to avoid conflicting results and 
unexpected losses, future canine MDSC studies should be done with fresh 
blood samples. 
 
6. Canine glioma patients have elevated levels of arginase activity. One 
of the most important mechanisms by which MDSC disrupt T-cell function 
is by reducing the availability of L- arginine, which impairs T-cell 
proliferation and cytokine production, and reduces the expression of TCR 
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CD3ζ chain (40, 59, 95). Several groups have found high arginase activity 
in plasma from cancer patients (40, 50, 59, 114). We also observed 
significantly elevated levels of arginase activity in the samples from canine 
glioma patients relative to healthy control dogs. We speculate that this 
increase in arginase activity could be due to an increased number of 
MDSC in the peripheral blood of these dogs with cancer. However, we 
were unable to correlate the arginase activity with the capacity of MDSC to 
suppress T cells since we did not use fresh blood samples on which 
functional studies can be performed. Therefore, further studies should be 
done with fresh blood samples to provide evidence of this association. 
 
7. Mouse CD11b but not Gr-1 antibody cross-react with canine cells. 
The mouse MDSC phenotype has been established as positive 
expression of the myeloid markers, CD11b+ and GR+, and can be further 
characterized as Ly6G+ or Ly6C+ for the granulocytic and monocytic 
subsets, respectively. Although there has been an increase in the 
availability of canine specific reagents, they are still limited. Therefore 
identification of antibodies that cross-react with canine species can greatly 
aid comparative research. Krol et al. describe the use of mouse Gr-1 
antibody to identify of myeloid precursors in canine mammary tissues 
using immunohistochemical staining (117). In our previously published 
study, the Gr-1 antibody clone (RB6-8C5) used by Krol, and the anti-
mouse CD11b clone (M1/70), were assess cross-reactive double labeling 
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of myeloid cells and staining was observed with both antibodies. In the 
current study, we performed additional tests to evaluate the specificity of 
these antibodies for the MDSC subset of myeloid cells. Unfortunately our 
current data demonstrated that the anti-mouse CD11b stained canine 
myeloid cells, but the anti-mouse Gr-1 clone did not. Flow cytometry 
analysis of cells stained with Gr-1 and CD11b antibodies revealed that Gr-
1 stain was only detected when canine gamma globulin blocking was not 
performed, while CD11b stain was positive with and without blocking. In 
addition, we performed IHC analysis of Gr-1 antibody stain on canine 
bone marrow and lymph nodes samples using mouse splenic tissue as the 
positive control. Again, mouse Gr-1 antibody failed to stain the canine 
tissues but did stain the mouse splenic tissue. Therefore, our data using 
anti-mouse Gr-1 conflicts with that of Krol et al. (117). Overall, this data 
suggests that anti-mouse Gr-1 antibody binding to canine cells may be 
nonspecific and this marker should not be used to identify MDSC in dogs. 
However isolation of the cells nonspecifically stained with Gr-1 antibodies 
and co-culture with responder PBMCs confirmed that highly suppressive 
cells are indeed present in the peripheral blood of dogs with cancer. 
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Future Directions: 
Although somewhat limited by the lack of available reagents for canine 
research, our studies validated the presence of MDSC in canine cancer patients 
and underlined the potential role of these cells in the immunosuppression in dogs 
with cancer. This was the first set of studies investigating MDSC in this species 
and future research to better define the phenotype and function of this cell 
population in dogs with cancer should be conducted.  
From a translational perspective based on the human literature, future 
studies on canine MDSC should include the use of markers for mature 
lymphocytes, such as CD3, CD4, CD8, CD5, CD21, for gating analysis of a 
lineage negative population. Importantly, all of these surface markers are 
commercially available for canines. A single specific marker for NK cells has not 
yet been identified in dogs, however recent publications demonstrate that these 
cells are characterized as a CD5- phenotype within a population of cells 
expressing the MHCII marker (127), therefore these cells would be excluded 
from our MHCII- MDSC pool. It was recently demonstrated that CD124 or IL4Rα 
expression on monocytic MDSC correlates with highly immunosuppressive 
function (84, 120), and a cross-reactive polyclonal IL4R-α antibody is 
commercially available. Studies should be carried out to evaluate whether this 
cell surface marker is present on canine monocytic MDSC and could be used to 
identify and isolate this population. Another potential marker that could be tested 
for further immunophenotyping of the granulocytic MDSC subset in canine blood 
is CD11/18. CD11/CD18 are β2 integrins that play a key role in the activation, 
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adhesion, migration, and phagocytosis of neutrophils (128). Knowing that 
granulocytes upregulate the expression of CD11/CD18 upon activation, we 
propose that this marker could be used in dogs as an analogue to CD66b in 
humans  
Cryopreservation reduces the viability of MDSC and certain sample 
handling and PBMC isolation protocols can cause variability in the PBMC 
fraction. Therefore to prevent inaccurate analyses, future studies of canine 
MDSC should be performed using fresh whole blood samples. Moreover, while 
there is accumulating evidence implicating ARG-1, iNOS2, TGF-β and IL10 in the  
mechanisms of inhibition, quantitative studies are needed to confirm the roles 
each of these candidate molecules are play in mediating the immunosuppression 
in the various tumors. Similarly, quantitative studies to assess whether potential 
tumor-derived factors, such as GM-CSF, VEGF, S100A8/ S100A9 proteins, 
PGE2 and COX-2 are involved in MDSC accumulation in dogs. Tumor cell 
supernatant has been used to show direct involvement of cancer cells in MDSC 
generation and accumulation; normal neutrophils and/or monocytes can be 
differentiated into MDSC by in vitro culture with conditioned media from 
malignant tumors (69, 70, 83, 121). These experiments are also feasible in 
veterinary medicine and may offer meaningful results. Recent canine study has 
shown that myeloid cells exposed to soluble tumor-derived factors decreased 
expression of MHC class II and CD80, reduced phagocytic activity, and 
suppressed the proliferation of responder immune cells. (129)  
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Finally, new therapeutic approaches, such as the use of PDE-5 inhibitors, 
COX-2 inhibitors, and kinase inhibitors, to decrease the number of MDSC and 
thereby improve T cell function in canine cancer patients should be tested. COX-
2 inhibitors, commonly know as NSAIDs, are widely used in both human and 
veterinary medicine to relieve pain and inflammation, and could easily be 
incorporated into immunotherapeutic protocols. Sunitinib, a tyrosine kinase 
inhibitor approved by the FDA to treat renal cell carcinoma patients, significantly 
decreased circulating MDSC and Tregs in renal cell cancer patients resulting in 
improved T cell function (60). Recently, the FDA approved Palladia, a tyrosine 
kinase inhibitor, for the treatment of mast cell tumors in dogs. This drug could be 
employed to target MDSC to enhance the response to immunotherapy (130, 
131). Pharmacologic agents that regulate MDSC recruitment, differentiation or 
expansion, and inhibit their suppressive function may be useful to control cancer 
growth and progression and provide more effective responses to immunotherapy. 
Altogether the results of our research demonstrate for the first time that 
similar to mice and humans, MDSC accumulate in the peripheral blood of canine 
cancer patients and have a potent ability to suppress T cell responses. Our 
studies were completed using peripheral blood of dogs with various tumor types 
including sarcomas, carcinomas, mast cell tumors, and glioma. Elevated 
numbers of suppressive MDSC were detected in the peripheral blood of all 
canine cancer patients regardless of tumor type compared of healthy control 
dogs with evidence of cancer. Importantly, this study characterized a three 
surface marker immunophenotype that can be used for future studies in dogs to 
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identify MDSC, paving a way to monitor MDSC burden in canine cancer clinical 
trials as a potential biomarker to offer insights into the efficacy of the new 
treatments that may benefit human cancer patients as well. 
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